

ANNUAL REPORT 2019

CHANGMAO BIOCHEMICAL ENGINEERING COMPANY LIMITED

常茂生物化學工程股份有限公司

(A Joint Stock Limited Company Incorporated In The People's Republic Of China)

(Stock Code: 954)



CONTENTS


•	Corporate Profile	2
•	Corporate Information	4
•	Chairman's Statement	5
•	Management Discussion and Analysis	11
•	Profile of Directors, Supervisors and Senior Management	14
•	Corporate Governance Report	20
•	Environmental and Social Report	32
•	Report of the Directors	40
•	Report of the Supervisory Committee	56
•	Independent Auditor's Report	58
•	Consolidated Statement of Comprehensive Income	65
•	Consolidated Balance Sheet	66
•	Consolidated Statement of Changes in Equity	68
•	Consolidated Cash Flow Statement	69
•	Notes to the Consolidated Financial Statements	70
•	Five Year Summary	134
•	Glossary	135

CORPORATE PROFILE

Established in 1992, Changmao Biochemical Engineering Company Limited is a leading organic acid producer in the PRC. Changmao produces organic acids products for sales to food additive, chemical and pharmaceutical industries. Changmao's products conform to the highest international standards and are sold domestically and exported to overseas such as Europe, Asia Pacific and America.

The core products of the Group are organic acids and their derivatives with four carbons in their structures including fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid and aspartame. These products are mainly used as food additives or medical inter-mediaries. The Group's major products are produced along vertical production chains. The major advantage of the production chains is that each of the products in the production chains is also a finished product for sales to customers.

PRODUCTION FLOWCHART OF CHANGMAO'S PRODUCTS




CORPORATE PROFILE

The Group persists in pursuing advanced technologies as its production direction and focuses in investment in new technology research and development which combines the production process with theoretical concepts. The Group received numerous awards in relation to production technologies including First Prize in Technological Achievement (技術發明一等獎) and Second Prize in Scientific Improvement (科技進步二等獎) in The Petroleum Chemical Industry in China (中國石油化工行業). The Group attained the ISO9001 Quality System Standards, Environmental Management System ISO14001 and FSSC22000 Food Safety System Certification. Its core product, L(+)-tartaric acid obtained the Food and Drug Administration (FDA) certificate. The Group's logo was also recognised as a Famous Trademark in the PRC (中國馳名商標).

The Group's major competitive edge is its delicate and advanced production system. Changmao successfully applied the theoretical concepts of enzyme technology and chirotechnology in its highly efficient and cost effective production process. The Group has two research and development centres, Chirotechnology Centre which is based in Changzhou, and the Shanghai Medical Life Science Research Centre Limited to research on new products and new production technologies. The Group will continue the production of food additives as its core business and develop new nutraceutical products to extend its production chain. The Group believes its strong capability in research and development would enable the Group to continue to grow.

GROUP STRUCTURE



CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Mr. Rui Xin Sheng (Chairman)
Mr. Pan Chun (Chief Executive Officer)

NON-EXECUTIVE DIRECTORS

Mr. Zeng Xian Biao Mr. Yu Xiao Ping Ms. Leng Yi Xin Mr. Wang Jian Ping

INDEPENDENT NON-EXECUTIVE DIRECTORS

Prof. Ouyang Ping Kai Ms. Wei Xin Ms. Au Fung Lan

SUPERVISORS NOMINATED BY SHAREHOLDERS

Ms. Zhou Rui Juan Mr. Lu A Xing

SUPERVISOR NOMINATED BY EMPLOYEES

Mr. Zhang Jun Peng

INDEPENDENT SUPERVISORS NOMINATED BY SHAREHOLDERS

Prof. Jiang Yao Zhong Mr. Geng Gang

COMPANY SECRETARY

Ms. Wan, Pui Ling Alice (CPA)

AUTHORISED REPRESENTATIVES

Mr. Rui Xin Sheng Ms. Wan, Pui Ling Alice (CPA)

COMPLIANCE OFFICER

Mr. Rui Xin Sheng

AUDIT COMMITTEE

Prof. Ouyang Ping Kai Ms. Wei Xin* Ms. Au Fung Lan

REMUNERATION COMMITTEE

Mr. Rui Xin Sheng* Prof. Ouyang Ping Kai Ms. Wei Xin Ms. Au Fung Lan

NOMINATION COMMITTEE

Mr. Rui Xin Sheng Prof. Ouyang Ping Kai* Ms. Wei Xin Ms. Au Fung Lan

LEGAL ADDRESS

No. 1228 Chang Jiang Bei Road New North Zone Changzhou City Jiangsu Province, 213034 The PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 54, 5/F, New Henry House 10 Ice House Street Central Hong Kong

PRINCIPAL BANKERS

Bank of China Changzhou Branch, the PRC Industrial and Commercial Bank of China Changzhou Branch, the PRC

HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited 46th Floor Hopewell Centre 183 Queen's Road East Hong Kong

AUDITORS

PricewaterhouseCoopers
Certified Public Accountants and
Registered PIE Auditor

COMPANY'S WEBSITE ADDRESS

www.cmbec.com.hk

STOCK CODE

954

^{*} chairman of the relevant committee

To the shareholders,

Results for the Year

In 2019, the Group's production and operation was stable and promoted the continuous growth of economic benefits. The Group's sales revenue for the year ended 31 December 2019 was approximately Rmb494,580,000 representing a decrease of approximately 22.6% as compared with that of Rmb639,120,000 in last year; the net profit attributable to equity holders of the Company was approximately Rmb58,299,000. This is an increase of approximately 15.4% over that of Rmb50,525,000 in last year.

The Group continuously improves technology innovation and upgrades management. The production of maleic anhydride using the butane-method brought in cost advantage and energy efficiency. With the advantages from production along product chains, the increase in the selling price of the major products and the stable cost of raw materials in 2019, the Group have promoted the continued growth of economic benefits.

Affected by the upgrading and improvement of environmental protection facilities in the fourth quarter of 2019, the Group's Changzhou plant suspended production from October to November, which imposed certain restrictions on the supply of some best-selling products and thus reduced sales and affected sales revenue of the fourth quarter and even the whole year. As a result, the Group's overall sales in 2019 showed a downward trend compared with that in 2018.

Business Review

The Group maintains competitive by adhering to the sales strategy of differentiated competition, making use of the advantages of large-scale production, and improving the production management and production technologies and continuously improving the quality of its products. At the same time, in order to meet customers' needs for different usages of the products, the Group has communicated with customers in depth and provided customers with product technical services and support, which are well recognised by the customers. Through the efforts of these years, the Group has accumulated a number of high-end customers with long-term cooperation and gained a stable market share.

In 2019, the Group's production line was the first in China to transform from using benzene-method to butane-method to manufacture maleic anhydride. The maleic anhydride production team continued to explore and break through technical difficulties to improve both output and quality of the maleic anhydride production. By using butane instead of benzene as a raw material to manufacture maleic anhydride, the price difference between butane and benzene has achieved a reduction of production costs from the source and has gained substantial energy efficiency from the by-product, steam, which can be recycled. This has laid a solid foundation for the Group's continued improvement in economic efficiency in 2019.

Saving energy, reducing emission and costs and improving efficiency are the focuses of the production management for the Group. In order to meet the ever-increasing safety and environmental protection standards, the Group has implemented automation and intelligent transformation on the production lines and infrastructure improvements. The Group has paid attention to details and continuously innovates and optimizes the production processes. Optimal allocations of different energy levels helped to improve the comprehensive utilization of energy, reduce the cost of purchased energy, and achieve the goals of energy saving, emission reduction, improving production efficiency.

For a long time, the Group's aim is "To create value for customers and create benefit for the company" and has carried out various daily management tasks. The Group strives in achieving high standards with strict requirements, continuously updates and upgrades management system. The Group has implemented refined management in actual production operations, promoted the 5S management system, effectively organised and rectified the production lines and improved the working environment. The Group has improved the enthusiasm of employees by rational recommendations and organising labour competitions. By clarifying the assessment of responsibility, labor productivity has been improved, which promoted the long-term healthy development of the Group.

Safety management has always been the top priority of the Group's production management. In 2019, the Group focused on the implementation of safety diagnostics, established a safety production information management platform, carried out safety upgrades to the production lines of the Changzhou plant, implemented closed management of the Class A area, and increased the safety precaution capabilities of each production lines. For a long time, the Group has adhered to the promotion of safety management standardisation, strengthening the training of employees' safety awareness, approving and supervising safety operations seriously. The Group has continuously performed self-improvement during the production process, implemented rectification, strengthened safety precautions and reduced accidents.

The Group conscientiously followed the requirements in relation to environment protection imposed by the government at all levels and continued to increase investment in this respect. The Group took measures to save energy, reduce cost and reduce emissions of wastes. The Group improves its self-monitoring process to ensure the strict adherence to the 3 major types of pollutant discharge standards and actively fulfilled the corporate social responsibility beyond corporate profits. In the fourth quarter of 2019, at the request of the government of the industrial park where the Group's Changzhou factory is located, some environmental improvement work had been carried out and the Changzhou plant temporarily suspended production. The management of the Group responded positively, made prompt decisions with its best efforts, implemented the rectification as soon as possible and resumed production in December.

In 2019, in order to reduce customs clearance time and costs, reduce the inspection rate of export products by the customs, and improve trade competitiveness, the Group's Changzhou factory passed the AEO (Authorized Economic Operator Certified Operator) customs certification, AEO customs certification is a way to promote the construction of the social credit system, establish an enterprise import and export credit management system, and a channel to promote trade security and convenience.

Research and Development

1. New Vitamin PQQ Project

In 2019, the Group's research and development team continued carrying out on the application and approval of using new vitamin PQQ as a new feed additive, researching on the medium trail production process and promoting PQQ's application. The Group submitted the application materials and supplementary editing materials to the Ministry of Agriculture and participated in a new vitamin expert review meeting organised by the Ministry of Agriculture in December. At the meeting, the economic feasibility and applicability of PQQ were recognised by the expert group. At the same time, the Group's research and development team is conducting tests on the critical points of the PQQ production process, with a view to improve its market competitiveness and accelerate the marketisation process

2. Pharmaceutical Adjuvant Project

To extend its product chain and enhance added value of products, the Group carried out the development project of pharmaceutical adjuvant. The product breadth has extended from food additives to pharmaceutical adjuvant. In 2019, the Group expanded the range of pharmaceutical adjuvant by increasing three new types of pharmaceutical adjuvant, DL-tartaric acid, maleic acid and fumaric acid. Pharmaceutical adjuvant is the Group's focus in the medium to long run. The Group will continue to promote the research and development of pharmaceutical adjuvants, increase product categories, increase sales efforts, and achieve economic benefits.

3. Active Pharmaceutical Ingredient Project

The country's policy on drug approval and the reform on deepening drug trial and strengthening drug supervision have brought a broad market for API. In 2019, the Group actively promoted cooperation projects with relevant units on the development of APIs as an extension of products on the Group's product chains, the Provincial Food and Drug Administration has given great support and guidance, which made us improved the effectiveness of our research and development and upgraded our production field equipment and facilities. The API is an update and upgrade to the existing products of the Group and an effective way to increase the added value of the products. It will contribute to the long-term economic benefits of the Group in the future.

Lianyungang Project

Since its establishment, Lianyungang Changmao has strictly complied with various national laws and regulations for project design, application and plant construction. In the initial stage of investment, the Group focused on the construction of safety and environmental protection on overall engineering facilities in the plant area. The large-scale wastewater treatment system in the plant area was designed by a professional design institute with a daily processing capacity of 1,000 tons and passed the examination of experts. A regenerative thermal oxidizer (RTO) tail gas incinerator is installed in the plant area to treat the organic tail gas generated during the production process to ensure compliance with standards. In order to ensure production safety, the production unit uses distributed control system (DCS) and independent instrument automation safety control system.

Since 2018, Jiangsu Province has continued to strengthen the rectification of the enterprises in Lianyungang City, especially those in the two chemical parks of Guanyun and Guannan, all of which had been suspended production. During this period, Lianyungang Changmao continued to upgrade the security facilities in the factory in accordance with the specifications in the documents issued by the provincial and municipal government. It has achieved personnel positioning in the production area. It also installed a video surveillance system and passed the national security level 2 standards. The production areas, warehouses and Class A tank farms all passed the fire inspection. The Group will continue to actively promote the matters related to the resumption of production and promptly resume production at Lianyungang Changmao.

The Environmental Protection Facilities of Lianyungang Changmao



Anaerobic Fermentation Internal Components



Hydrolysis Acidification Treatment System



Sludge Sedimentation System



Regenerative Thermal Oxidizer (RTO) Incineration System

Outlook and Prospects

The Group adheres to the technology innovation for its development and promotes its work based on customer needs. As a manufacturing enterprise, the Group always adheres to the principle of quality first, customer first, and relies on the advantages of the existing product chains and economic benefits to maintain its leading position in the industry. In the future, the Group will continue to reduce costs and increase efficiency, expand the scale effect, continuously improve product quality and service, and firmly establish the image of Changmao brand, and will focus on the following aspects:

- 1. Accelerating technology innovation and promoting product upgrade

 Technological innovation is the driving force for long-term development of enterprises. The

 Group will continue to increase investment in technological innovation and consolidate
 its existing resources and research team. By relying on technological advancement and
 speeding up the development of new vitamin PQQ, pharmaceutical adjuvant, APIs and
 other new products, it will cultivate new products which are safe, environmentally
 friendly and with strong competitiveness. Moreover, it will optimise its product structure,
 promote the upgrading and extension of existing product chains, and enhance the Group's
 competitiveness in the high-end product market, and to seek new profit source of the Group.
- 2. Promoting the development of Lianyungang project and taking advantages of production scale
 Lianyungang Changmao is a major development project of the Group in the near future.
 The construction of the new production plant in Lianyungang aimed to enhance the Group's product chain and advantages from economy of scales, provide strong support for the Group in the industry competition of the world's high-end food, pharmaceutical and new materials and will inject new development momentum into the Group.
- 3. Enhancing safety and environmental protection standards and strengthening risk control
 With the laws and regulations related to safety and environmental protection becoming
 stricter, the elimination process of small and medium-sized enterprises that failed to meet
 the standards were accelerated, leaving the industry to further concentrated on strong
 enterprises that complied with the relevant requirements. The Group has strictly complied
 with various safety and environmental regulations and this has transformed it into a
 competitive advantage. In terms of safety, the Group will continue to strengthen safety
 control, pay attention to safety risks, improve the safety of the production environment, and
 eliminate safety accidents in the future. In terms of environmental protection, the Group
 will continue to promote clean production and implement pollution prevention, endeavour
 to become an environment-friendly enterprise which save energy and reduce emissions of
 wastes which helps to reduce the impact of policy risks on production and operation, and
 create a resource-saving and environment-friendly enterprise to pave the way for the Group's
 sustainable development.

- 4. Focusing on market expansion and develop markets of high-end customers

 The Group's sales team is dedicated to develop and maintain end-customers and superior customers. It is customer-oriented. By meeting customer needs through the improvement of product quality and service, enhancing the reputation and adding value to the Changmao brand, the overall competitive advantages are enhanced. In addition, the Group will also focus on the development of the international market, and enhance the international reputation and influence of Changmao through cooperation with new international customers in new products and technologies.
- 5. Promoting Domestic A Shares Listing Project
 In consideration of the long-term development of the Group, the Board has approved the proposal to apply to the relevant securities regulatory authorities for issuance of A shares of the Company on the Shanghai Stock Exchange or the Shenzhen Stock Exchange pursuant to the Company Law of the PRC, the Securities Law of the PRC and other relevant laws, regulations and regulatory documents. As at the date of this report, the Company has not determined the plan of the proposed A Share offering and has not applied to any regulatory authorities in the PRC or anywhere else for the approval of the Proposed A Share Offering. In 2020, the Group will make every effort to implement the specific investment plan and A shares issuance plan, promote the listing of A shares in the PRC, and make the Group become a company listed with A and H shares.

There will be opportunities and challenges in the future. The Group will continue the production of food additives as its core business and will increase the competitiveness of its existing products by exploring new markets and new application areas. The Group will capitalise its research and production strengths to extend its production chain, to become bigger and stronger with great results.

The Group's long-term and stable development relies on the strong support from all shareholders. I would like to express my most sincere gratitude to the investors on behalf of the Board.

Rui Xin Sheng Chairman

The PRC, 27 March 2020

MANAGEMENT DISCUSSION AND ANALYSIS

ANALYSIS OF KEY PERFORMANCE INDICATORS

Revenue (2019: Rmb494,580,000; 2018: Rmb639,120,000) and gross profit margin (2019: 27.3%; 2018: 20.3%)

The decrease in revenue was mainly due to the decrease in sales volume compared to that in 2018. Affected by the improvement of environmental protection facilities in the fourth quarter of 2019, the Group's Changzhou plant suspended production from October to November, which caused certain restrictions on the supply of some best-selling products and reduced sales, which affected the sales of the fourth quarter and even that of the full year.

After the completion of the transformation of the maleic anhydride production lines in the Changzhou headquarter in the first half of 2018, the Group has resumed stable production after subsequent adjustment. The cost saving effect of these transformed production lines played full effect in 2019. By using butane instead of benzene as a raw material to manufacture maleic anhydride, the Group has reduced production costs from the source and has gained substantial energy efficiency from the by-product, steam, which has resulted in a significant increase in the Group's economic efficiency, reduced production cost and increased profit margin in 2019.

Selling and administrative expenses (2019: Rmb75,025,000; 2018: Rmb78,723,000)

Selling and administrative expenses included a profit-based bonus of Rmb3,146,000 for the year ended 31 December 2019 (2018: Rmb1,809,000). Excluding this bonus, the level of selling and administrative expenses decreased as compared to that of last year because the Changzhou factory has suspended production for two months in the fourth quarter of 2019 during which period, expenses decreased.

Other (losses)/gains, net (2019: losses of Rmb1,066,000; 2018: gains of Rmb1,737,000)

The net losses for the year ended 31 December 2019 was mainly attributable to the increase in loss on disposal of property, plant and equipment by approximately Rmb2,065,000.

Finance costs, net (2019: Rmb257,000; 2018: Rmb853,000)

The decrease in interest expense was due to the decrease in average bank loans compared to that in last year.

Income tax expense (2019: Rmb4,626,000; 2018: Rmb4,692,000)

The Company, being qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15% for the year ended 31 December 2019. Other subsidiaries of the Group in Mainland China are subject to a standard tax rate of 25%. Tax credit resulted for the year ended 31 December 2019 mainly because of the recognition of deferred tax assets on tax loss of a subsidiary. For details of the difference on the tax on the Group's profit before income tax and the theoretical amount that would arise using the weighted average tax rate applicable to the results of the consolidated entities, please refer to Note 9 to the consolidated financial statements.

Profit for the year attributable to the equity holders of the Company

For the year ended 31 December 2019, the Group recorded a profit attributable to equity holders of the Company of approximately Rmb58,299,000 (2018: Rmb50,525,000), which was higher than that in last year. The increase in net profit was mainly due to the increase in gross profit margin, the contribution of Changzhou headquarters maleic anhydride production line to the cost control, and the continuous improvement of operating efficiency.

MANAGEMENT DISCUSSION AND ANALYSIS

SEGMENTAL INFORMATION

Some of the Group's products are exported to Europe, Asia Pacific and America. As expressed as a percentage of revenue, export sales (excluding sales through import-export agents in the PRC) accounted for approximately 47% (2018: 49%) of the Group's revenue while domestic sales in the PRC accounted for approximately 53% (2018: 51%) of the Group's revenue.

EXPOSURE TO FLUCTUATIONS IN EXCHANGE RATES AND RELATED HEDGES

The Group mainly operates in the PRC. Substantially all of its assets, liabilities and capital expenditure are located or incurred in Mainland China. Sales are made to customers in the PRC as well as overseas customers while purchases are mainly from suppliers in the PRC. The Group is therefore exposed to foreign exchange risk arising from currency exposures, primarily with respect to USD. Management periodically monitors foreign currency exposures and considers hedging significant foreign currency exposure should the need arises. The Group used forward foreign exchange contracts to partially hedge the USD exposures during the year. As at 31 December 2019, the Group had outstanding forward foreign exchange contracts with fair value amounted to Rmb43,000.

LIQUIDITY AND FINANCIAL RESOURCES

As at 31 December 2019, the Group had total outstanding bank borrowings of Rmb20,500,000 (2018: Rmb39,311,000). The outstanding bank borrowings as at 31 December 2019 were unsecured and were all repayable within one year. The Company expects to renew the bank borrowings in due time if necessary. The average effective interest rate of all the outstanding bank loans as at 31 December 2019 was approximately 3.9% (2018: 3.8%) per annum.

Except for the bank borrowings disclosed above, as at 31 December 2019 and 2018, the Group did not have any committed borrowing facilities.

The Group generally finances its operations with equity fundings and bank borrowings. Excess cash held by the Group is generally placed at banks to earn interest income or invested in wealth management products of low risks with banks.

As at 31 December 2019, the Group had capital commitments for property, plant and equipment amounting to approximately Rmb6,652,000 (2018: Rmb12,328,000). These capital commitments are mainly used for the modification of production lines. The Group intends to finance the capital commitment by cash flows generated from the Group's operations and/or bank financings.

The Group did not have any charge on its assets during the year ended 31 December 2019. The liabilities-to-assets ratio (calculated based on total liabilities divided by total assets) was 10.2% (2018: 13.8%) as at 31 December 2019. As at 31 December 2019, the Group's cash and cash equivalents amounted to Rmb119,316,000 (2018: Rmb81,398,000). The Directors believe that the Group is in a healthy financial position.

MANAGEMENT DISCUSSION AND ANALYSIS

EMPLOYEES

Including the Directors and Supervisors, as at 31 December 2019, the Group employed a total of 461 employees (2018: 479 employees). Employees are remunerated in accordance with the nature of the job and also on individual merit. Total amount of staff costs for the year ended 31 December 2019 was approximately Rmb65,477,000 (2018: Rmb69,859,000). The incentive bonus for the directors and staff of the Group was Rmb3,146,000 (2018: 1,809,000) for the year ended 31 December 2019. Excluding the incentive bonus, the cost of staff wages, benefits and retirement was approximately Rmb62,331,000 (2018: Rmb68,050,000), which was lower than that in 2018 because (i) the average number of employees was lower than that of last year and (ii) the Changzhou factory has suspended production for two months in the fourth quarter of 2019 during which period, wages were paid as usual, but overall staff costs decreased.

Under the staff incentive scheme for each of the three years ended 31 December 2022, so long as the audited profits (or, where applicable, combined or consolidated profits) attributable to the shareholders (after taxation and non-controlling interest (if any) but before payment of the bonuses referred to below) amount to not less than Rmb40 million (the "Target Profit"):

- (a) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable to Mr. Rui Xin Sheng as a bonus for the relevant year;
- (b) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable to the general manager and all the Directors (other than Mr. Rui Xin Sheng and the independent non-executive Directors) for the time being of the Company as a bonus for the relevant year; and
- (c) a sum equivalents to 5% of the amount in excess of the Target Profit will be payable as bonus to all the employees (including supervisors, but excluding the Directors and the independent supervisors) of the Company and its subsidiaries (if any) from time to time, the basis of apportionment of which will be determined by the Board at its discretion.

SIGNIFICANT INVESTMENTS

There are no significant investments held by the Group as at 31 December 2019 and 2018.

CHANGES IN THE COMPOSITION OF THE GROUP DURING THE YEAR

There are no material acquisitions and disposals of subsidiaries and affiliated companies by the Group during the year ended 31 December 2019.

CONTINGENT LIABILITIES

As at 31 December 2019 and 2018, the Group did not have any material contingent liabilities.

DIRECTORS

Executive Directors

Mr. Rui Xin Sheng (芮新生), aged 63, is the chairman of the Board, an executive Director and the compliance officer of the Company. He is a researcher and a senior engineer of the Company. He was one of the founders of the Company in December 1992. He is also the director of Shanghai Life Sci, director and authorised representative of Shanghai Changmao and the director of Changmao (Hong Kong) Company Limited. Mr. Rui graduated from Jiangsu Institute of Technology (江蘇化工學院) with a bachelor degree in organic synthesis in 1982. He obtained an executive master of business administration in the Nanjing University (南京大學) in 2005. He is the vice chairman of the Committee of Biochemical Engineering of the Chemical Industry and Engineering Society of China (中國化工學會生物化工專業委員會), the deputy managing director of the Association of Biochemistry of China (中國生物化工協會), the deputy managing director of Jiangsu Commission of Biotechnology (江蘇省生物技術協會) and a part-time professor at the Nanjing University of Technology (南京工業大學). Owing to his significant achievement in the field of biochemistry, Mr. Rui received numerous awards including the First Class Award of Scientific Development and Technology Improvement in Changzhou (常州市技術改造一等獎) and the Second Prize of Changzhou City Scientific and Technological Achievement (常州市科技進步二等獎) in 1997. The Concurrent Production Technology invented by Mr. Rui, Ms. Leng Yi Xin and Mr. Jiang Jun Jie obtained patent in the PRC in 1998. Other awards obtained by Mr. Rui include the Fourth Annual Excellent Scientists of Changzhou City (常州市第四屆傑出科技人員) in 1999, DuPont Innovation Award and Youth Expert with Excellent Contribution in Jiangsu Province (江蘇省有突 出貢獻的中青年專家) in 2000, the First Class Award of State Technological Achievement (國家科 技進步一等獎) in 2001, Innovative Entrepreneur of Jiangsu Province (江蘇省創新創業人才獎), the Second Class Award of Petrol Chemical Industry Technological Achievement in the PRC (中國石油 化學工業行業科技進步二等獎) in 2003 and the First Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步一等獎) in 2005. He is currently a director of Shuguang Factory. Mr. Rui is the spouse of Ms. Leng Yi Xin (a non-executive Director).

Mr. Pan Chun (潘春), aged 50, is an executive Director and the general manager (chief executive officer) of the Company. He is also the director and authorised representative of Lianyungang Changmao. He obtained a bachelor degree in industrial analysis from the department of applied chemistry of the Nanjing University of Technology (南京工業大學) in 1993. Mr. Pan is recognised as a senior engineer by the Jiangsu Provincial Personnel Department (江蘇省人事廳). Mr. Pan is responsible for the management of production, safety, environment protection, equipment management, purchasing and domestic sales of the Company. Mr. Pan received the First Class Award of Changzhou Technological Achievement (常州市技術改造一等獎) in 1997. Mr. Pan received the First Class Award of Technological Invention (技術發明一等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2003, May 1st Labour Medal of Changzhou City (常州市五一勞動獎章) in 2011 and Model Worker of China Light Industry (中國輕工行業勞動模範) in 2012. Mr. Pan joined the Company in August 1993.

DIRECTORS (Continued)

Non-executive Directors

Mr. Zeng Xian Biao (曾憲彪), aged 77, is a non-executive Director. Mr. Zeng graduated from Nanjing Petrochemistry School (南京石油工業學校) in 1961. He has extensive experience engaging in research, development and production management in the field of chemistry. Mr. Zeng received various awards including the Golden Prize of Technological Improvement-Maleic Anhydride 2000t/a (順酐2000t/a技改省金牛獎) from the State Economic Commission (國家經濟委員會), Maleic Anhydride 3000t/a Technology Improvement (3000t/a順酐重點技改先進個人), Municipal Contribution Award for the Ninth Five-year Period and the Millennium (市九五跨世紀奉獻獎) and the Second Annual State Award for Technological Development (省第二次合理化建議科技成果獎). Mr. Zeng joined the Company in December 1992.

Mr. Yu Xiao Ping (虞小平), aged 64, is a non-executive Director. Mr. Yu graduated from East China Normal University (華東師範大學) with a bachelor degree in English in 1977. He holds directorships in various pharmaceutical and investment companies in the PRC. Besides his experience in trading of pharmaceutical products, he has experience in promoting and facilitating the inspection and approval from the U.S. Food and Drug Administration for various PRC pharmaceutical products, of which he became the executive agent for these pharmaceutical products and has established a trading business in the United States of America. Mr. Yu joined the Company in December 1992.

Ms. Leng Yi Xin (冷一欣), aged 58, is a non-executive Director. She is also the director of Shanghai Life Sci and general manager of Shanghai Changmao. She graduated from the Jiangsu Institute of Technology (江蘇化工學院) with a bachelor degree in organic synthesis in 1982 and subsequently obtained a master degree in chemical engineering from Nanjing University of Technology (南京工業大學) in 1996 and obtained a doctorate in bio-chemical engineering from Nanjing University of Technology in 2005. She is also a professor of the department of chemical engineering of the School of Petrochemical Engineering in Changzhou University (常州大學石油化工學院). Ms. Leng has participated in various research projects and published more than 50 theses. As mentioned above, Ms. Leng is one of the inventors of the Concurrent Production Technology. She obtained the Second Class Award of Technological Invention (技術發明二等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2004. She also obtained the First Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步一等獎) in 2005 and the Third Class Award of Jiangsu Province Technological Achievement (江蘇省科學技術進步三等獎) in 2010. She is the spouse of Mr. Rui (the chairman of the Board and an executive Director). She joined the Company in June 2001.

Mr. Wang Jian Ping (王建平), aged 58, is a non-executive Director. He graduated from Shanghai Jiao Tong University (上海交通大學) with a bachelor of engineering degree in 1983 and subsequently obtained a master of engineering degree from Shanghai Jiao Tong University (上海交通大學) in 1986. Mr. Wang is currently a general manager of Shanghai Technology Entrepreneur Investment Company Limited (上海科技創業投資股份有限公司). Mr. Wang has been a director of the 704 Research Centre of the Seventh Institute of the China Shipping Company (中國船舶總公司七院704研究所) and a visiting scholar of the department of energy in the University of Leeds. Mr. Wang was first appointed as a non-executive Director in June 2007.

DIRECTORS (Continued)

Independent non-executive Directors

Prof. Ouyang Ping Kai (歐陽平凱), aged 74, is an independent non-executive Director. He graduated from Tsinghua University (清華大學) with a bachelor degree in 1968 and subsequently obtained a master degree in chemistry research from the same university in 1981. From 1985 to 1987, he was a visiting scholar of the University of Waterloo, Ontario, Canada. Prof. Ouyang is an academician of the Chinese Academy of Engineering (中國工程院). He was the President of Nanjing University of Technology (南京工業大學) and instructed dozens of master and doctorate students. He also holds memberships and positions in various science and academic institutions. Prof. Ouyang obtained various awards including the First Prize of the State Technological Achievement (國家科技進一等獎) in 2001, the Technology Achievement Award from the Ho Leung Ho Lee Foundation, Dupont Innovation Award and several other awards of national level. Prof. Ouyang published more than 180 theses and two publications. Prof. Ouyang was first appointed as an independent non-executive Director in June 2001.

Ms. Wei Xin (衛新), aged 52, is an independent non-executive Director. Ms. Wei is a certified public accountant in the PRC. She graduated from Soochow University (蘇州大學) in accountancy in 1989. She has over fifteen years of experience in auditing and accounting. Ms. Wei is currently the partner of a certified public accounting firm in the PRC. Ms. Wei was first appointed as an independent non-executive Director in September 2004.

Ms. Au Fung Lan (歐鳳蘭), aged 45, is an independent non-executive Director. Ms. Au has over 12 years of experience in investment banking in Hong Kong. Ms. Au holds a bachelor degree of commerce from the University of Toronto in 1997. Ms. Au is currently the executive director of an investment bank in Hong Kong. Ms. Au was first appointed as an independent non-executive Director in June 2013.

SUPERVISORS

Supervisors nominated by Shareholders

Ms. Zhou Rui Juan (周瑞娟), aged 65, is a Supervisor and the chairman of the supervisory committee of the Company. She is also the supervisor of Shanghai Changmao. She graduated from Changzhou Light Industrial School (常州輕工學校) majoring in corporate management in 1988. Ms. Zhou passed the State Examination for Assistant Accountant in 1997. She was a financial accountant, the vice manager of the labour department and the director of the administrative department of the Company. Ms. Zhou was recognised as an activist of the labour union (工會積極分子) and an advanced worker (先進生產者) of the Company. She joined the Company in January 1993.

Mr. Lu A Xing (陸阿興), aged 51, is a Supervisor and a manager of the sales department of the Company. He obtained a diploma from Changzhou Chemical Worker's School (常州市化工職工學校) in 1988 and continued his studies at The Chinese Communist Party School of Jiangsu Province (中共江蘇省委黨校). Mr. Lu has over 20 years' experience in sales and marketing. Mr. Lu joined the Company in January 1993.

Supervisor nominated by employees

Mr. Zhang Jun Peng (張俊朋), aged 46, is a Supervisor and the chief officer of the concurrent production line of the Company and an engineer. He graduated from Jiangsu Institute of Petrochemical Technology (江蘇石油化工學院) in 1997 with a bachelor degree in chemical engineering. He was engaged in the continuous improvement and innovation of four-carbon series organic acid and obtained the Second Class Award of Process Innovation & Technological Invention (創新工藝技術發明二等獎) from China Petroleum and Chemical Industry Association (中國石油和化學工業協會) in 2004. Mr. Zhang was involved in various projects of the Company in respect of the improvement of production technology and is experienced in the production management of the Company. The concurrent production line led by Mr. Zhang won the championship of "the Cup of Safety and Health" ("安康杯"競賽優勝班組) in China in 2012 from the All-China Federation of Trade Unions (中華全國總工會) and the State Administration of Work Safety of the PRC (國家安全生產監督管理總局). He joined the Company in August 1997.

SUPERVISORS (Continued)

Independent Supervisors nominated by Shareholders

Prof. Jiang Yao Zhong (蔣耀忠), aged 83, is an independent Supervisor. He graduated from the department of chemistry of Peking University (北京大學) in 1957. He has been the vice president of the Chengdu branch of the Chinese Academy of Sciences (中國科學院成都分院) during 1990 to 1994. He was also the president of Chengdu Institute of Organic Chemistry, the Chinese Academy of Sciences (中國科學院成都有機化學研究所) during 1992 to 1997 and the scientific consultant of the Government of Sichuan Province from 1988 to 1998. He was a committee member of the Chemistry Society of China (中國化學會), a deputy director of the Committee of the Organic Chemistry (有機化學委員會), a chairman of the board of Sichuan Institute of Chemistry and Chemical Engineering (四川省化學化工學會), a member of the review panel of Department of Chemical Science of National Natural Science Foundation of China (國家自然科學基金委員會 化學部評審組成員) and a foreign member of the American Chemical Society and the chief editor of Synthetic Chemistry (合成化學) from 1998 to 2002. He is a researcher and an instructor of doctorate students in Organic Chemistry, the Chinese Academy of Sciences (中國科學院成都有 機化學研究所). Prof. liang was recognised as the Leader of Academy and Technology in Sichuan (四川省學術和技術帶頭人) in 1998 and awarded the Prize of Creation in Organic Synthesis by the Chemistry Society of China (中國化學會有機合成創造獎) in 2000. He also received the Second Class Award of National Natural Science Award (國家自然科學二等獎) in 2005, the Thomson Reuters Research Front Award in 2008, and Educator with Outstanding Contributions (傑出貢獻 教師) from the Graduate University of the Chinese Academy of Sciences (中國科學院研究生院) in 2008. Prof. Jiang was first appointed as an independent Supervisor in June 2004.

Mr. Geng Gang (耿剛), aged 59, is an independent Supervisor. He graduated from Jingsu Institute of Chemistry (江蘇化工學院) in 1982. He possesses over 20 years of experience in the field of chemical industry. Mr. Geng is recognised as a senior engineer by the Jiangsu Provincial Personnel Department (江蘇省人事廳). Mr. Geng is currently a deputy chief engineer, a director of laboratory and senior engineer of a chemical company and the vice chairman of the Technical Committee of China Cellulose Association (中國纖維素協會技術委員會). He obtained the Third Class Award of Jiangsu Science and Technology Progress (江蘇省科技進步三等獎) and the Second Class Award of Wuxi Science and Technology Progress (無錫市科技進步二等獎) for his research on the pilot-scale project of making viscose-styrene grafting fiber in 1990. He obtained the award of Wuxi Excellent Scientific Workers (無錫市優秀科技工作者稱號) in 1991 and the award of Wuxi Top Youth Expert (無錫市中青年專業技術拔尖人才) in 1992. Mr. Geng was first appointed as an independent Supervisor in June 2010.

SENIOR MANAGEMENT

Mr. Pan Chun (潘春), whose personal particulars are set out under the paragraph headed "Directors" in this section.

Mr. Wan Yi Dong (萬屹東), aged 46, is the deputy general manager of the Company. Mr. Wan is a senior engineer certified by Human Resources and Social Security Department of Jiangsu Province (江蘇省人力資源和社會保障廳(省人社廳)認定的高級工程師). He graduated from Zhejiang University in 1996 with a bachelor degree in biochemistry. In 2004, he obtained a master degree in business administration from Nanjing University of Science and Technology. He joined the Company in August 1996. He was engaged in the technology advancement of bio-enzyme and immobilised enzyme technology and has been involved in various projects of the Company in respect of improvement in production technology and new technology on new products. Mr. Wan has published various professional articles in professional chemical magazines. He obtained various awards including the 常州市科技進步一等獎 (The First Class Award of Changzhou City Technological Achievement) in 2001 and 中國石油和化學工業協會科技進步二等獎 (The Second Class Award of Petrol Chemical Industry Technological Achievement in the PRC) in 2003. Mr. Wan joined the Company in August 1996.

Ms. Zhang Qin Ying (張琴英), aged 51, is the deputy general manager of the Company. She is also the supervisor of Lianyungang Changmao. She is a senior economist. She studied in Finance School of Changzhou (常州財經學校), specializing in financial management in 1999. She has also studied in The Chinese Communist Party School of Jiangsu Province in 2007, specializing in economic management. She has years of strong management experience in finance and labour union. She also serves as the chairman of the Union of Chemical Industry of Changzhou (常州市化工行業工會) and vice-chairman of the Union of Chemical and Light Industry in Changzhou (化輕產業工會). Ms. Zhang joined the Company in September 1993.

Ms. Wan, Pui Ling Alice (温珮玲) (CPA), aged 48, is the financial controller and company secretary of the Company. She has over twenty years of experience in accounting and financial management in Hong Kong and the PRC. Ms. Wan holds a bachelor degree in business administration and a master of science degree in finance from the Chinese University of Hong Kong, and is an associate member of the Hong Kong Institute of Certified Public Accountants. Ms. Wan joined the Company in June 2001.

Mr. Lu A Xing (陸阿興), whose personal particulars are set out under the paragraph headed "Supervisor" in this section.

Save as disclosed above, each of the Directors or Supervisors does not have any relationship with any directors, supervisors, senior management, management shareholders, substantial shareholders, or controlling shareholders of the Company (within the meaning of the Listing Rules).

The Company is committed to the maintaining of a high standard of corporate governance. The Company believes that good corporate governance provides a framework that is essential for effective management, a healthy corporate culture, successful business growth and enhancing shareholders' value.

COMPLIANCE WITH CODE PROVISIONS OF THE CODE ON CORPORATE GOVERNANCE PRACTICES

The Board is responsible for performing the corporate governance duties set out in the terms of reference in D.3.1 of the CG code.

Throughout the year ended 31 December 2019, the Company complied the code provisions of Corporate Governance Code and Corporate Governance Report as set out by the Stock Exchange in Appendix 14 to the Listing Rules, with the exception of Code Provisions A.6.7 (directors attending general meetings).

Code provision A.6.7 of CG Code stipulates that non-executive Directors and independent non-executive Directors should attend general meetings. Mr. Pan Chun, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Mr. Wang Jian Ping, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan were unable to attend the annual general meeting held on 10 May 2019, due to prior business commitments.

The Company's corporate governance structure includes the Board and the supervisory committee. The Company has also established three committees under the Board, namely the Remuneration Committee, the Audit Committee and the Nomination Committee. The corporate governance practices adopted by the Company are as follows:

THE BOARD

The major responsibilities of the Board include the formation of the Group's overall strategies, setting business plans and the supervision of the performance of the management. The Directors acknowledge their responsibility for preparing the financial statements on a going concern basis, with supporting assumptions or qualifications as necessary. The Board is also responsible for preparing a balanced, clear and understandable assessment of annual and interim reports, price-sensitive announcements and other disclosures required under the Listing Rules and other statutory requirements.

As at 31 December 2019, the Board comprises two executive Directors, namely, Mr. Rui Xin Sheng (Chairman) and Mr. Pan Chun (General Manager), four non-executive Directors, namely, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Ms. Leng Yi Xin and Mr. Wang Jian Ping and three independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Ms. Wei Xin and Ms. Au Fung Lan.

The roles of the chairman and chief executive (i.e. general manager) of the Company are separate and exercised by different individuals.

The Board meets regularly, and had met five times for the year ended 31 December 2019. Attendance of individual members of the Board meeting for the year ended 31 December 2019 is as follows:

	Name of Director	Attended/Eligible to attend
Executive Directors	Rui Xin Sheng (Chairman)	5/5
	Pan Chun (General Manager)	5/5
Non-executive Directors	Zeng Xian Biao	5/5
	Yu Xiao Ping	5/5
	Leng Yi Xin	5/5
	Wang Jian Ping	4/5
Independent Non-executive Directors	Ouyang Ping Kai	0/5
	Yang Sheng Li (Note)	2/2
	Wei Xin	4/5
	Au Fung Lan	5/5

Save that Ms. Leng Yi Xin is the wife of Mr. Rui Xin Sheng, each of the Directors is independent of other Directors.

Note: Prof. Yang Sheng Li resigned on 17 June 2019.

Code of Conduct Regarding Securities Transactions by Directors

The Company has adopted the Model Code as its own code of conduct regarding securities transactions by Directors.

The Company had also made specific enquiry of all Directors in relation to the compliance of the Model Code. Save for the above, the Company was not aware of any non-compliance with the Model Code for the year ended 31 December 2019.

Independent Non-executive Directors

The Company has received from each of the independent non-executive Directors an annual confirmation of his/her independence pursuant to Rule 3.13 of the Listing Rules and the Company still considers the independent non-executive Directors remained independent.

Continuous Professional Development

Directors' training is an ongoing process. During the year, Directors received regular updates and presentations on changes and developments to the Group's business and to environments in which the Group operates. All Directors are also encouraged to attend relevant training courses at the Company's expense. All Directors are required to provide the Company with his or her annual training record.

The Directors participated in the continuous professional developments in relation to regulatory update, the duties and responsibility of the Directors and the business of the Group in the following manner:

	Directors	Types of training
Executive Directors	Rui Xin Sheng	В, С
	Pan Chun	В, С
Non-executive Directors	Zeng Xian Biao	В
	Yu Xiao Ping	В
	Leng Yi Xin	В
	Wang Jian Ping	В
Independent non-executive Directors	Ouyang Ping Kai	В
	Wei Xin	В
	Au Fung Lan	A, B

A: attending seminars provided by external parties

B: reading materials in relation to regulatory update

C: attending internal training sessions provided by the Company

BOARD COMMITTEES

Remuneration Committee

The Remuneration Committee was established to ensure there are formal and transparent procedures for developing and overseeing the Company's policies on the remuneration of its directors and senior management. As at 31 December 2019, the Remuneration Committee comprises three independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Ms. Wei Xin and Ms. Au Fung Lan and an executive Director, Mr. Rui Xin Sheng (chairman of the committee). The Remuneration Committee makes recommendations to the Board on the remuneration packages of individual executive Directors and senior management. The Remuneration Committee held one meeting in 2019 to assess the performance of the executive Directors and review the policy for the remuneration of the Directors and how the Group complied with the staff incentive bonus scheme as stated below. The meeting attendance rate of individual members for the year ended 31 December 2019 was as follows:

Name of committee member

Attended/Eligible to attend

Rui Xin Sheng	1/1
Ouyang Ping Kai	1/1
Yang Sheng Li (Note)	1/1
Wei Xin	1/1
Au Fung Lan	1/1

Note: Prof. Yang Sheng Li resigned on 17 June 2019

The remunerations of Directors and senior management are based on the skill, knowledge and involvement in the Company's affair of each Director or senior management and are also determined with reference to the performance and profitability of the Group. The Company has formulated a staff incentive bonus scheme. Details of which is set out in the paragraph headed "Employees" under the section headed "Management Discussion and Analysis".

Audit Committee

The Company has established an audit committee with written terms of reference in compliance with the Listing Rules. As at 31 December 2019, the Audit Committee comprises three independent non-executive Directors, namely, Prof. Ouyang Ping Kai, Ms. Wei Xin (chairman of the committee) and Ms. Au Fung Lan.

The primary duties of the Audit Committee are to review and to provide supervision over the financial reporting process and internal control system of the Group, to review the Group's financial information and to review the audit plan, audit findings and independence of the auditors of the Company. The Audit Committee held five meetings for the year ended 31 December 2019, two of which were with the attendance of the external auditor. The meeting attendance rate of individual members for the year ended 31 December 2019 was as follows:

Name of committee member

Attended/Eligible to attend

Ouyang Ping Kai	5/5
Yang Sheng Li (Note)	2/2
Wei Xin	5/5
Au Fung Lan	5/5

Note: Prof. Yang Sheng Li resigned on 17 June 2019

Duties performed by the Audit Committee for the year were as follows:

- 1. made recommendations to the Board on the re-appointment of the external auditor, and to approve the remuneration and terms of engagement of the external auditor;
- 2. reviewed and monitored the external auditor's independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, discussed with the external auditor the nature and scope of the audit and reporting obligations before the audit commences:
- 3. reviewed the Group's financial information, monitored the integrity of the Group's financial statements and the annual report and accounts and half-year report and reviewed significant financial reporting judgements contained in them. In reviewing these reports before submission to the Board, the Committee had focused particularly on:
 - (i) any changes in accounting policies and practices;
 - (ii) major judgmental areas;
 - (iii) significant adjustments resulting from audit (if any);
 - (iv) the going concern assumptions and any qualifications;
 - (v) compliance with accounting standards;
 - (vi) compliance with the Listing Rules and legal requirements in relation to financial reporting; and
 - (vii) consider any significant or unusual items that are, or may need to be, reflected in the report and accounts;

4. reviewed the Group's financial controls and internal controls, among others, by discussing the internal control system with the management to ensure that the management has performed its duty to have an effective internal control system; reviewed the Group's financial and accounting policies and practices; and reported to the Board on the matters in the CG Code.

Nomination Committee

The Nomination Committee was established to formulate and implement the nomination policy and Board Diversity Policy, nominate candidates of Directors for election by shareholders and to assess the independence of independent non-executive Directors. As at 31 December 2019, the Nomination Committee comprises three independent non-executive Directors, namely, Prof. Ouyang Ping Kai (chairman of the committee), Ms. Wei Xin and Ms. Au Fung Lan and an executive Director, Mr. Rui Xin Sheng.

The Nomination Committee held one meeting in 2019 to review the structure, size and composition of the Board and to assess the independence of independent non-executive Directors. The meeting attendance rate of individual members for the year ended 31 December 2019 was as follows:

Name of committee member

Attended/Eligible to attend

Rui Xin Sheng	1/1
Ouyang Ping Kai	1/1
Yang Sheng Li (Note)	1/1
Wei Xin	1/1
Au Fung Lan	1/1

Note: Prof. Yang Sheng Li resigned on 17 June 2019

POLICY FOR NOMINATION OF DIRECTORS

Procedures for Nomination and Appointments of Directors

Appointments of Directors, being individuals who are suitably qualified and expected to make positive contributions to the performance of the Board, are first considered by the Nomination Committee and then by the Board. Thereafter, all Directors are subject to election by shareholders at the shareholders' general meeting. A Director may serve consecutive terms if re-elected upon the expiration of the terms.

Each of Mr. Rui Xin Sheng and Mr. Pan Chun has entered into a service agreement with the Company. All the other Directors have not entered into any service agreement with the Company. The terms of each Director is not more than three years and will be expired on 17 June 2022.

Nomination of Candidates for Re-election of Directors

The terms of the sixth session of the Directors has expired on 17 June 2019. Except for Prof. Yang Sheng Li who decided not to stand for re-election, all retiring Directors were eligible and had offer themselves for re-election at the AGM held on 10 May 2019. Prof. Yang Sheng Li has confirmed that he has no disagreement with the Board or supervisory committee of the Company and nothing relating to the affairs of the Company needed to be brought to the attention of the shareholders of the Company.

On 8 March 2019, the Nomination Committee, having reviewed the Board's composition, nominated all the existing Directors (except for Prof. Yang Sheng Li) to the Board for it to recommend to Shareholders for re-election at the AGM held on 10 May 2019. The nominations were made in accordance with the Nomination Policy and the objective criteria (including without but not limited to skills, regional and industry experience, background, race, gender and length of service), with due regard for the benefits of diversity, as set out under the Board Diversity Policy. The Nomination Committee had also taken into account the Board performance evaluation for the past three years, confirmed that all the existing Directors continue to contribute effectively and are committed to their roles. Although Prof. Ouyang Ping Kai and Ms. Wei Xin have served as independent non-executive Directors for more than 9 years, they meet the independence factors set out in Rule 3.13 of the Listing Rules and are not involved in the daily management of the Company, nor in any relationships or circumstances which would interfere with the exercise of their independent judgment. In addition, they continue to demonstrate the attributes of independent non-executive directors and there is no evidence that their tenure have had any impact on their independence. Taking into account of the above, the Nomination Committee is of the opinion that Prof. Ouyang Ping Kai and Ms. Wei Xin remain independent notwithstanding the length of their service and it believes that their valuable knowledge and experience in the Group's business and their general business acumen continue to generate significant contribution to the Company. Accordingly, the Nomination Committee, in accordance with the Nomination Policy and Board Diversity Policy, nominated all the existing Directors to stand for election by Shareholders at the Annual General Meeting held on 10 May 2019. On 12 March 2019, the said nominations were accepted by the Board with each candidate abstaining from voting on the proposition of himself for election by Shareholders. All the candidates for re-election of Directors do not have any service contracts with any member of the Group that are not determinable by the Group within 1 year without compensation (other than statutory compensation).

Board Diversity Policy


The Group has adopted a board diversity policy (the "Board Diversity Policy"). A summary, together with the measurable objectives set for implementing this policy, and the progress made towards achieving those objectives are disclosed as below.

Summary of the Board Diversity Policy and Measurable Objectives

The Company recognises and embraces the benefits of diversity in the Board. The Company believes that a diversity of perspectives can be achieved through consideration of a number of factors, including but not limited to skills, regional and industry experience, background, race, gender and other qualities. In performing its perspective on diversity, the Company will also take into account factors based on its own business model and specific needs from time to time. The Company endeavours to ensure that its Board has the appropriate balance of skills, experience and diversity of perspectives that are required to support the execution of its business strategies and in order for the Board to be effective. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

Implementation and Monitoring

The Nomination Committee reviewed the Board's composition under diversified perspectives, and monitored the implementation of the Board Diversity Policy annually. As at the date of this report, the Board's composition under major diversified perspectives was summarized as follows:



THE SUPERVISORY COMMITTEE

The supervisory committee is accountable to the general meeting. The primary responsibilities of the supervisory committee include the monitoring of whether the Directors and senior management have, in the performance of their duties, acted in contravention of any laws, administrative regulations, the Articles of Association of the Company or the resolutions passed at general meetings; and the reviewing of the Company's financial information. Supervisors can attend the Board meetings.

The supervisory committee comprises two supervisors nominated by shareholders, Ms. Zhou Rui Juan and Mr. Lu A Xing, a supervisor nominated by employees, Mr. Zhang Jun Peng and two independent supervisors nominated by shareholders, Prof. Jiang Yao Zhong and Mr. Geng Gang. Each of Mr. Lu A Xing, and Mr. Zhang Jun Peng has entered into a service agreement with the Company. Ms. Zhou Rui Juan, Prof. Jiang Yao Zhong and Mr. Geng Gang have not entered into any service agreement with the Company. The terms of each supervisor is not more than three years and will be expired on 17 June 2022.

The supervisory committee held two meetings for the year ended 31 December 2019 with attendance rate of 100%.

COMPANY SECRETARY

The Company Secretary, Ms. Wan, Pui Ling Alice, is responsible for facilitating the Board process, as well as communications among Board members, with shareholders and management. She reports to the Board Chairman and the general manager of the Company. The Company Secretary's biography is set out in the "Profiles of Directors, Supervisors and Senior Management" section of this Annual Report. During 2019, the Company Secretary undertook over 15 hours of professional training to update her skills and knowledge.

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Directors acknowledge their responsibility for preparing the financial statements for the year ended 31 December 2019, which give a true and fair view of the state of affairs of the Group at that date and of the Group's profit and cash flows for the year then ended and are properly prepared on the going concern basis in accordance with the statutory requirements and applicable accounting standards.

The statement of the Auditor of the Company about its reporting responsibilities on the consolidated financial statements of the Company is set out in the Independent Auditor's Report on pages 58 to 64.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board is responsible for ensuring sound and effective risk management and internal control systems to safeguard the shareholders' interests and the Company's assets. The risk management and internal control systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

The successful management of risks is essential for the long-term growth and sustainability of the Group's business. The Board is responsible for setting strategies, business objectives and risk appetite as well as ensuring a review of effectiveness of the risk management and internal control systems, and oversees management in the design, implementation and monitoring of the risk management and internal control systems. In 2019, the management have provided a confirmation to the Board on the effectiveness of such systems. The Board also reviewed the Group's risk management and internal control systems, which the Board considers to be adequate and effective in 2019. The level of resources, staff qualifications and experience, training programs and budget of the Company's internal audit and accounting and financial reporting functions were assessed and considered adequate.

A management committee has been established to ensure that significant risks are identified; assessed by considering the impacts and likelihoods of their occurrence; and effectively managed by identifying suitable controls and countermeasures, and assessing the cost effectiveness of the mitigating actions proposed. With the assistance of the this committee, the Board continuously monitors the company's risk management framework, reviews the Group's significant risks and emerging risks, and conducts an annual review of the effectiveness of the risk management system. The Board determines the nature and extent of significant risks it is willing to take in achieving the strategic objectives of the Group. Each department of the Group is responsible for identifying its own risks and designing, implementing and monitoring the relevant risk management and internal control systems. The process involves the maintenance of risk register setting out the particulars of material risks together with the control measures as reported by significant departments of the Group. It ensures that significant risks are considered by the Board in determining their risk appetite.

A risk management policy has been adopted to serve as a guideline for risk management and internal control systems.

Internal audit

Internal control system shall allow monitoring of the Company's overall financial position; safeguard its assets against major losses and misappropriation; provide reasonable assurance against material fraud and errors; and efficiently monitor and correct non-compliances.

During the year, the Company had transactions derived from bank borrowing occurred with a related party. Please refer to Note 33(b) of the consolidated financial statements. The Company obtained confirmation letters from the relevant banks stating that these loans did not constitute violations of any regulations. As of the date of this report, all of these loans have been repaid on schedule. The Group will continue to improve its internal control system to ensure its effective implementation.

The Company does not have an internal audit department but has engaged an external professional party to perform internal audits to evaluate the proper functioning of the internal control systems for the year ended 31 December 2019. It is intended to carry out this evaluation process on an ongoing basis. The Audit Committee, after reviewing and considering the management findings from the internal control report, then reported to the Board of the Company and confirmed to the Board that the internal control systems are effective and adequate.

Inside Information Policy

The Board approved and adopted an Inside Information Policy which contains the guidelines to the Directors, officers and all relevant employees (likely possessing the unpublished inside information) of the Group to ensure that the inside information of the Group is to be disseminated to public in equal and timely manner in accordance with the applicable laws and regulations. Such procedures include, among others, notification of regular blackout period and securities dealing restrictions to relevant Directors and employees, identification of project by code name and dissemination of information to stated purpose and on a need-to-know basis have been implemented by the Group to guard against possible mishandling of inside information within the Group.

AUDITOR'S REMUNERATION

PricewaterhouseCoopers have been re-appointed as the Company's international external auditor by the shareholders at the 2019 annual general meeting. They are primarily responsible for providing audit services in connection with the Company's annual financial statements.

During the year, the remuneration to the external auditor in Rmb equivalent is as follow:

	2019	2018
	Rmb′000	Rmb′000
Auditors' remuneration – Audit Service	1,321	1,367

DIVIDEND POLICY

The Company's policy is to provide dividends to shareholders which is linked to the underlying performance of business. The Board considers that it would be prudent and appropriate to target a pay-out ratio of 30% to 70% per cent of the Group's consolidated net profit attributable to the equity holders of the Company. The actual dividend pay-out ratio, however, may cause some deviation from the target, depending on the cash flows and future funding requirements of the Company.

SHAREHOLDERS' RIGHTS

Convening an extraordinary general meeting

Pursuant to Article 61 of the Articles and Associations of the Company, shareholder(s) holding 10% or more of the Company's issued capital that carry voting rights request(s) in writing for the convening of an extraordinary general meeting, the board of Directors shall convene an extraordinary general meeting within 2 months.

Procedures for putting forward proposals at shareholders' meeting

Pursuant to Article 63 of the Articles and Associations of the Company, when the Company convenes a shareholders' annual general meeting, shareholder(s) holding 5% or more of the total shares carrying voting rights of the Company are entitled to propose new matters in writing to be considered, and the Company shall include in the agenda of that meeting those matters contained in the proposal which are within the scope of the duties of the general meeting provided that the proposal is delivered to the Company within 30 days from the issue of the notice of the meeting.

Procedures for nominating a new Director

Pursuant to Article 97 of the Articles and Associations of the Company, a notice of the intention to propose a person for election as Director and the written notice by such candidate of his/her willingness to accept the nomination shall be given to the Company no less than seven days. The minimum seven-day period of lodgement by the shareholders of notice to nominate a Director shall commence no earlier than the date after the despatch of the notice of the meeting appointed for such election and end no later than seven days before the date of such meeting.

Communications with Shareholders

The Board always welcome Shareholders' and other stakeholder's questions and concerns relating to the Group's management and governance. Shareholders and other stakeholders may at any time send their enquiries and concerns to the Board by addressing them to Company Secretary by post. The address is Room 54, 5th Floor, New Henry House, 10 Ice House Street, Central, Hong Kong.

Articles of Association

The Company has not revised the Articles of Association to the Company during the year ended 31 December 2019.

By order of the Board

Rui Xin Sheng Chairman

The PRC, 27 March 2020

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Board is well aware of the importance of environmental protection on the Group's sustainability and stable development, and at the same time strives to improve product quality while achieving the best balance between cost control and environmental protection. The Group has established an environmental management system based on the actual situation and its factory in Changzhou obtained ISO14001 certification. The Group aims to be a resource-saving and environment-friendly enterprise with low energy and resources consumption and low level of discharge on wastages. The Group promotes clean production, prevents pollution and reduces the risk of environmental accidents. The Group's environment protection department dedicates to strengthen its environmental protection, actively implements environmental policies, vigorously carries out environmental management, and takes energy-saving measures to achieve reduction on pollution. At the same time, the Group also has a full-time environmental protection workshop to treat the wastewater of each production line in a centralised manner and discharges it into the sewage treatment company of the industrial area. In addition, the environmental protection department conducts centralised management and treatment of solid waste and hazardous waste in the production lines, and the production tail gas is collected and put into spray adsorption tower or regenerative thermal oxidizer for incineration treatment. Therefore, the Group's business activities have no significant impact on the environment and natural resources.

All of the Group's production is conducted in Mainland China. The Group is required to comply with the environmental protection laws and regulations promulgated by the national and local governments of the PRC. Some of these regulations govern the level of fees payable to government entities providing environmental protection services and the prescribed standards relating to the discharge of solid wastes, effluent and gases. The Group's production technology enables the Group to effectively control the pollution caused by the production process. The Group has installed waste disposal facilities to reduce waste discharge. The Group did not aware of any material violations of the laws and regulations on environmental protection in 2019.

The following discussion and information on the environment are the combined information of the Group's factories in Changzhou and Lianyungang. The Changzhou maleic anhydride production line of the Group fully played its effects in 2019. Using a new method to produce maleic anhydride significantly reduced greenhouse gas emissions. The Group's Lianyungang plant continued to suspend production due to local government policies. In addition, the Group's plant in Changzhou has also temporarily suspended production in the fourth quarter of 2019 due to local government environmental requirements. Based on the above factors, the main key performance indicators on environmental protection in this year have decreased.

I. Emissions

As the Group is mainly engaged in production, the following discussion on emissions is mainly related to the emissions from production.

(1) Greenhouse gases emission

The Group has carbon dioxide emissions. There are no requirements under the PRC rules and regulations to measure these greenhouse gases. In order to reduce costs and emissions, the Group started in 2018 using butane to replace benzene as a raw material for production. Using of butane to produce maleic anhydride will reduce carbon dioxide emissions. It is cleaner and more environmentally friendly and in line with the international trend of food additive production.

The Group's indirect greenhouse emissions are mainly from electricity and steam consumption. In order to reduce steam consumption, the Group recycles the steam output from the maleic anhydride production line. This not only can reduce greenhouse gas emissions, but also reduce production costs. In order to reduce emissions, the Group is committed to ensure the efficient operation of the equipment and the implementation of cleaner production. Hazardous and non-hazardous wastes are mainly disposed of by qualified waste disposal companies for incineration or recycling.

(2) Sewage and noise

The Group employs independent environmental monitoring companies to measure sewage water quality and noise emissions annually for its plants. The emissions in 2019 are within the limits set by the national standards.

Key Performance Indicators

,	2019	2018
Amount of waste water in total (in tonnes)	393,492	451,557
Amount of waste water - Per unit of output		
(in tonnes/tonne)	13.84	13.92
Exhaust gas in total (in tonnes)	8.24	17.94
Exhaust gas – Per unit of output (in tonnes/tonne)	0.000	0.001
Greenhouse gas emissions in total (in tonnes) (Note)	71,565	99,940
Greenhouse gas emissions in total – Per unit of output		
(in tonnes/tonne) (Note)	2.52	3.08
Hazardous waste produced in total (in tonnes)	1,111	1,787
Hazardous waste produced – Per unit of output		
(in tonnes/tonne)	0.04	0.06
Non-hazardous waste produced in total (in tonnes)	1,724	1,548
Non-hazardous waste produced – Per unit of output		
(in tonnes/tonne)	0.06	0.05

Note:

The Group converted its greenhouse gas emissions according to GBT32151.10-2015, "Requirements for the Greenhouse Gas Emissions Accounting and Reporting – Part 10: Chemical Production Enterprises (溫室氣體排放核算與報告要求一第10部分:化工生產企業)". It is the sum of direct and indirect greenhouse gas emissions from the Changzhou plant and Lianyungang plant.

The Group's direct greenhouse gas emissions related to n-butane, the raw material of Changzhou plant and Lianyungang plant. The amount of greenhouse gas converted the steam sold by the Group has been deducted from the total direct greenhouse gas emissions. When calculating the amount of direct greenhouse gas converted from steam, the emission factor for heat consumption is calculated based on the "2010 Shanghai Energy Balance Sheet and the GHG inventory compilation data (上海市2010年能源平衡表和温室氣體清單編製數據)".

The Group's indirect greenhouse gas emissions related to the emissions from purchase of electricity and heat by the two plants. The calculation of electricity emission factors used from electricity purchased is based on the latest data released by National Development and Reform Commission which the factor of East China Regional Power Grid (EFgrid, BM, y(tCO₂/MWh)) adopted in the calculation is 0.4923 (2018: 0.4923). The calculation of the heat-generating emissions factors of the thermal consumption purchased is based on the "2010 Shanghai Energy Balance Sheet and the GHG inventory compilation data" and the value taken is 0.11t CO₂/GJ.

II. Use of Resources

The Group is committed to reducing energy consumption. In the production process, the Group needs to use energy, including water, electricity and steam.

(1) Water

The Changzhou plant of the Group is accredited as a water-saving enterprise in Changzhou City. The Group adopted the municipal policies and plans to use water efficiently and save water usage. The Group clearly understood these directions and adopted effective measures. The effect is obvious in recent years with gradual reduction in water consumption per unit of product. The Group improved the production equipment, used water-saving technology to achieve the rational use of water resources, the Group has effectively controlled the discharge of recycled water, backwashed water for centralised reuse to achieve water-saving effect.

The Changzhou plant of the Group has passed the assessment and obtained "Water Balance Test Certificate (水量平衡測試合格證)" which indicated that the Group's water consumption level is reasonable. The Group uses water from local water companies and there is no any issue in sourcing water.

(2) Electricity

The Group has effectively used of power resources. The power supply bureau adopts the policy of "top, peak, valley and flat" charging policy, that is, different charges in different periods. Unit charges is the highest in the 'top period', and lowest at the 'valley period'. The Group actively cooperated with the relevant policies to raise the proportion of electricity consumption in the 'valley and flat period' to reduce the production costs.

(3) Steam

There are two sources of steam, one is purchase from third parties and the other is recovery and recycling of steam generated during the production process. Recycling of steam helps to reduce energy consumption and production costs. In terms of reducing energy consumption, the Group uses recycled steam to drive turbine to drive ventilator in production, reducing costs and increasing efficiency while achieving energy conservation and environmental protection. In addition, in the designed production process of Lianyungang plant, the steam that would generated during production will not only enough to recycle for its own use, there will be excess steam for selling to the nearby factory. It helps both to reduce steam emissions, and will also bring economic benefits to the Group.

(4) Packaging materials

There are different types of packaging materials. Packaging materials only accounted for a very small portion production costs. In 2019, packaging materials only accounted for less than 3% of the cost of production.

Key Performance Indicators

	2019	2018
Electricity consumption in total (in kwh)	33.1 million	43.3 million
Electricity consumption – Per unit of output		
(in kwh/tonne)	1,165	1,334
Steam consumption in total (sourcing from outside)		
(in tonnes)	124,865	169,657
Steam consumption (sourcing from outside)		
Per unit of output (in tonnes/tonne)	4.39	5.2
Water consumption in total (in tonnes)	447,927	636,216
Water consumption – Per unit of output (in tonnes/tonne)	15.76	19.6

SOCIAL

(I) Employment and Labour Practices

The Group's principle is people-oriented. It continuously improves the working environment and remuneration and to provide a broad developmental platform for the employees to display their individual talents. It has resolutely implemented the relevant national and local government laws and regulations in relation to employment. The Group has established a fine social accountability system, covering all aspects of employment regulations and social welfare. The Group provides its staff with a safe working environment by implementing the safety standard management and has accredited as the national "Second Grade Enterprise of Work Safety Standardisation" (安全生產標準化二級企業).

The Group attaches great importance to staff training. The Group provides trainings to staff which are relevant to their duties, including management, regulatory update, environment protection, food safety, team building, etc. The Group also encourages the employees to attend different kinds of colleges and universities courses and trainings to strengthen their academic qualifications which are related to their work duties by providing subsidies to them.

For safety training, management personnel involved in the production have to participate in safety training and pass the assessment by Changzhou production safety publicity and education centres. The Group's safety director and safety department organise trainings on relevant laws and regulations, safety knowledge, and enterprise management system for the person in charge of safety and head of different production lines each month. The safety department also organises training for staff working in the production lines on safety production and technology operation, techniques on operation of new equipment before commencement of new projects and production with new production technologies.

In addition, pay raise and benefits for employees every year are based on their performance. The Group organised different social activities every year, so that the employees in various positions of different departments of the Group can increase communication and strengthen interaction.

The Group strictly complies with the State Council's regulation on "Provisions on the Prohibition of Using Child Labour" on executing the employment standards, and has established recruitment procedures and measures to ensure that child labour is not employed. The vast majority of the Group's employees are Chinese. The Group is not aware of any violation of employment and labour laws and regulations nor any violation of child labour provisions in 2019.

Key performance indicators

The followings are key performance indicators in relation to the Group's employment and labour practices:

	2019	2018	2017
Number of employees (by gender)			
Male	313	326	409
Female	148	153	168
Number of employees (by employment type)			
Management	71	68	70
Production	307	320	406
Sales	26	26	29
Research and development	57	65	72
Number of employees (by age group)			

Training			
Training expenses	Rmb350,000	Rmb186,000	Rmb158,000
Percentage of employees trained	97%	98%	98%
Average training hours completed per			
employee	67	70	72

121

296

44

161

282

36

251

291

35

(II) Operating Practices

30 or under

31-50

Over 50

(1) Supply Chain Management

The Group has more than 100 qualified suppliers. To become qualified suppliers, their samples have to pass the examination, the trial production by the Group and suppliers' assessments. Performance of all suppliers for the previous year would be evaluated at the beginning of each year and they can continue as the Group's suppliers after passing the evaluation. Evaluation of new suppliers and subcontractors includes their commitment to social responsibility and performance. The Group has a procurement management systems and has developed a series of procurement control procedures for strict selection of suppliers and control the procurement process. Procurement staff regularly visits suppliers to maintain close contacts and good cooperation relations with them. The vast majority of the Group's suppliers are located in mainland China.

(2) Product Liability

After 20 years of accumulation, the Group's customers are all over the world. The Group has always focused on maintaining customer relationships. In recent years, the Group has continued to strengthen direct sales to end-users with a closer and long-term customer relation. The Group strictly controls its product safety and quality to maintain quality leadership and ensure customer satisfaction. The Group has met the highest standards in the food safety systems FSSC22000 and quality management system ISO9001. The Group conducts customer satisfaction survey each year to obtain customers' feedback and understand their requirements, as well as serve as an objective assessment to the Group. Reports show that the Group's customers were satisfied in 2019.

The Group has standard procedures to handle customer complaints. The Group has been focusing on product quality, and continuously improving the process to ensure product quality and strengthen brand management to meet potential complaints and ensure proper quality delivery.

The Group has a trademark management system and business ethics code control procedures, and strictly complies with the laws and regulations for protection of intellectual properties.

The Group has inspection and test control procedures to test the semi-finished products or finished products item by item. Standard procedures are in place to deal with each qualified or non-qualified products. There is a "certificate of analysis" for each finished product to facilitate product traceability. In case a product recall is triggered, the Group initiates a recall procedure, analyses the extent of the food hazard and classifies it, re-examines the products if necessary and makes a recall if needed based on the results of the analysis or examination. The Group would also record the number of products recalled to ensure that unsafe batch of products are fully and promptly recalled and are appropriately processed in accordance with the procedures for handling recalled products. In 2019, the Group has not recalled any sold or shipped products due to safety and health reasons.

The Group also endeavors to ensure the proper use of customer information. The Group has complied with the relevant national laws and regulations and the Group's internal business ethics control procedures when collecting, processing and using such information in the course of business.

(3) Anti-corruption

The Group has anti-corruption control procedures issued to all employees, and has mechanisms for employees to report problems found. The Group has management system and measures on fund management to prevent money laundering. The Group conducts an internal audit of social responsibilities every year to examine whether there are any bribery, extortion or fraud.

There was no significant risk associated with bribery identified in 2019. There was no concluded legal cases regarding corrupt practices brought against the Group or its employees. There were no confirmed incidents of contract termination or non-renewal of contract with business partners due to embezzlement during the year. During the year, the Group did not receive any reports in relation to corruption.

(III) Society

In terms of participating in social investment, the Group has made a Rmb190,000 donation to the Changzhou Charity Association in 2019.

The Directors have pleasure in submitting their report together with the audited consolidated financial statements for the year ended 31 December 2019.

PRINCIPAL ACTIVITIES AND GEOGRAPHICAL ANALYSIS OF OPERATIONS

The principal activities of the Company are the production and sale of organic acids products. The activities of the subsidiaries are set out in Note 18 to the consolidated financial statements.

An analysis of the Group's revenue for the year by geographic segments is set out in Note 5 to the consolidated financial statements.

RESULTS AND APPROPRIATIONS

The results of the Group for the year are set out in the consolidated statement of comprehensive income on page 65.

No interim dividend was declared during the year (2018: Nil). The Directors recommend the payment of a final dividend of Rmb0.055 (2018: 0.05) (inclusive of tax) per share for the year ended 31 December 2019 totalling approximately 29,134,000 (2018: Rmb26,485,000).

DONATIONS

Charitable and other donations made by the Group during the year amounted to Rmb190,000 (2018; Rmb140.000).

SHARE ISSUED IN THE YEAR

Details of the shares issued by the Company in the year ended 31 December 2019 are set out in Note 25 to the consolidated financial statements.

DISTRIBUTABLE RESERVES

As at 31 December 2019, the distributable reserves of the Company were approximately Rmb470,558,000 (2018: Rmb416,392,000) as reported in the statutory financial statements prepared in accordance with the PRC Generally Accepted Accounting Principles.

PRE-EMPTIVE RIGHTS

There is no provision for pre-emptive rights under the Articles of Association of the Company or the laws of the PRC, being the jurisdiction in which the Company was established, which provides the existing shareholders with pre-emptive rights to purchase new shares in any new issue of the Company according to their respective proportion of shareholding.

SUMMARY FINANCIAL INFORMATION

A summary of the published results and assets and liabilities of the Group for the last five years is set out on page 134 of the annual report.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities for the year ended 31 December 2019.

DIRECTORS AND SUPERVISORS

The Directors and Supervisors during the year were:

Executive Directors

Mr. Rui Xin Sheng (Chairman)

Mr. Pan Chun

Non-executive Directors

Mr. Zeng Xian Biao

Mr. Yu Xiao Ping

Ms. Leng Yi Xin

Mr. Wang Jian Ping

Independent non-executive Directors

Prof. Ouyang Ping Kai

Prof. Yang Sheng Li (resigned on 17 June 2019)

Ms. Wei Xin

Ms. Au Fung Lan

Supervisors nominated by shareholders

Ms. Zhou Rui Juan

Mr. Lu A Xing

Supervisor nominated by employees

Mr. Zhang Jun Peng

Independent Supervisors nominated by shareholders

Prof. Jiang Yao Zhong

Mr. Geng Gang

DIRECTORS AND SUPERVISORS (Continued)

The terms of each of the Directors and Supervisors will be expired on 17 June 2022. In accordance with Article 97, 116 and 117 of the Company's Articles of Association, Directors and Supervisors nominated by shareholders shall be elected at the shareholders' general meeting for a term of three years. Supervisor who is a representative of employees shall be elected by the employees of the Company for a term of three years. A Director or Supervisor may serve consecutive terms if re-elected upon the expiration of the terms.

DIRECTORS' AND SUPERVISORS' SERVICE CONTRACTS

Each of Mr. Rui Xin Sheng, Mr. Pan Chun, Mr. Lu A Xing, and Mr. Zhang Jun Peng has entered into a service agreement with the Company. All the other Directors and Supervisors have not entered into any service agreement with the Company.

Save as above, no Director or Supervisor who is proposed for re-election at the forthcoming Annual General Meeting has a service contract with the Company which is not determinable within one year without payment of compensation other than statutory compensation.

DIRECTORS' AND SUPERVISORS' MATERIAL INTEREST IN TRANSACTIONS, ARRANGEMENTS AND CONTRACTS THAT ARE SIGNIFICANT IN RELATION TO THE COMPANY'S BUSINESS

No transactions, arrangements and contracts of significance in relation to the Group's business to which the Company or its subsidiaries was a party and in which a Director, a Supervisor and a connected party of a Director or a Supervisor had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS

As at 31 December 2019, the interests (including interests in shares and short positions) of the Directors, Supervisors or chief executives of the Company in the shares, underlying shares and debentures of the Company or any specified undertaking of the Company or any other associated corporations (within the meaning of Part XV of the SFO), which were notified to the Company and the Stock Exchange pursuant to: (a) Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which each of them is taken or deemed to have taken under such provisions of the SFO); or (b) Section 352 of the SFO to be entered in the register referred to in that section; or (c) Appendix 10 of the Listing Rules relating to securities transactions by Directors; or (d) the Hong Kong Companies Ordinance (Cap. 622), to be notified to the Company and the Stock Exchange, were as follows:

Long positions in shares:

Director	Capacity	Number of Domestic Shares	Approximate percentage shareholding in the Domestic Shares (Note (k))	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares (Note (I))	Number of H Shares	Approximate percentage shareholding in the H Shares (Note (m))
Mr. Rui Xin Sheng	Beneficial owner, interest of spouse, interest of controlled corporation, trustee (other than a bare trustee) and custodian (Note (a))	2,500,000	100%	135,000,000	39.30%	3,820,000	2.08%
Ms. Leng Yi Xin	Beneficial owner, interest of spouse and interest of controlled corporation (Note (b))	2,500,000	100%	135,000,000	39.30%	3,820,000	2.08%
Mr. Pan Chun	(Note (c))	-	-	(Note (c))	(Note (c))	-	-
Mr. Zeng Xian Biao	(Note (d))	-	-	(Note (d))	(Note (d))	-	-
Mr. Yu Xiao Ping	Interest of spouse and interest of controlled corporation (Note (e))	-	-	66,000,000	19.21%	2,620,000	1.43%

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

Long positions in shares: (Continued)

Director	Capacity	Number of Domestic Shares	Approximate percentage shareholding in the Domestic Shares (Note (k))	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares (Note (I))	Number of H Shares	Approximate percentage shareholding in the H Shares (Note (m))
Prof. Ouyang Ping Kai	(Note (f))	-	-	(Note (f))	(Note (f))	-	-
Supervisor							
Ms. Zhou Rui Juan	(Note (g))	-	-	(Note (g))	(Note (g))	-	-
Mr. Lu A Xing	(Note (h))	-	-	(Note (h))	(Note (h))	-	-
Mr. Zhang Jun Peng	(Note (i))	-	-	(Note (i))	(Note (i))	-	-
Prof. Jiang Yao Zhong	(Note (j))	-	-	(Note (j))	(Note (j))	-	-

Notes:

(a) The 135,000,000 Foreign Shares are held by HK Xinsheng Ltd and the 2,500,000 Domestic Shares are held by Changzhou Xinsheng. Mr. Rui is the beneficial owner of 3,768,000 H Shares and 52,000 H Shares are held by Ms. Leng Yi Xin, spouse of Mr. Rui. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Mr. Rui is the registered holder and beneficial owner of 96,500 Class "A" shares. He is also the registered holder of 53,000 Class "B" shares and holds such shares as trustee in respect of a discretionary trust for the group of persons who made contribution to the Company or who from time to time make contribution to the Company. Mr. Rui is the registered holder and beneficial owner of 70% of the registered capital of Changzhou Xinsheng. Ms. Leng, a Director and the spouse of Mr. Rui, is also interested in HK Xinsheng Ltd and Changzhou Xinsheng, details of which are set out in Note (b) below.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

- (b) Ms. Leng is the registered holder and beneficial owner of 73,500 Class "A" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Ms. Leng is the registered holder and beneficial owner of 30% of the registered capital of Changzhou Xinsheng, which is the registered holder and beneficial owner of 2,500,000 Domestic Shares. Mr. Leng is also the beneficial owner of 52,000 H Shares. Mr. Rui, a Director and the spouse of Ms. Leng, is personally interested in shares of the Company and also interested in HK Xinsheng Ltd and Changzhou Xinsheng, details of which are set out in Note (a) above.
- (c) Mr. Pan is the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. He is also the registered holder and beneficial owner of 200,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (d) Mr. Zeng is the registered holder and beneficial owner of 380,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares. Mr. Zeng is also the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (e) Mr. Yu and his wife (who is not a Director) taken together are interested in the entire issued capital of Jomo Limited which is the registered holder and beneficial owner of 66,000,000 Foreign Shares. Mr. Yu's wife, Ms. Lam Mau, is also the beneficial owner of 2,620,000 H Shares.
- (f) Prof. Ouyang is the registered holder and beneficial owner of 4,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (g) Ms. Zhou is the registered holder and beneficial owner of 220,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS OR CHIEF EXECUTIVES IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY SPECIFIED UNDERTAKING OF THE COMPANY OR ANY OTHER ASSOCIATED CORPORATIONS (Continued)

- (h) Mr. Lu is the registered holder and beneficial owner of 220,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (i) Mr. Zhang is the registered holder and beneficial owner of 800 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares. Mr. Zhang is also the registered holder and beneficial owner of 120,000 shares in HK Biochem Ltd, which is the registered holder and beneficial owner of 67,500,000 Foreign Shares. The total number of issued shares in HK Biochem Ltd is 6,750,000 shares.
- (j) Prof. Jiang is the registered holder and beneficial owner of 2,000 Class "B" shares in HK Xinsheng Ltd, which is the registered holder and beneficial owner of 135,000,000 Foreign Shares. The issued share capital in HK Xinsheng Ltd comprises 170,000 Class "A" shares and 100,000 Class "B" shares.
- (k) The percentage is calculated based on the 2,500,000 Domestic Shares in issue as at 31 December 2019.
- (l) The percentage is calculated based on the 343,500,000 Foreign Shares in issue as at 31 December 2019
- (m) The percentage is calculated based on the 183,700,000 H Foreign Shares in issue as at 31 December

Save as disclosed above, as at 31 December 2019, none of the Directors, Supervisors or chief executives of the Company have interests in the shares, underlying shares and debentures of the Company or any specified undertaking of the Company or any other associated corporations (within the meaning of Part XV of the SFO) (including interests in shares and short positions) which were required to notify the Company and the Stock Exchange pursuant to: (a) Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which each of them is taken or deemed to have taken under such provisions of the SFO); or (b) Section 352 of the SFO to be entered in the register referred to in that section; or (c) Appendix 10 of the Listing Rules relating to securities transactions by Directors, and (d) the Hong Kong Companies Ordinance (Cap. 622) to be notified to the Company and the Stock Exchange.

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S RIGHT TO ACQUIRE SHARES OR DEBT SECURITIES

At no time during the year was the Company, of its subsidiaries or its other associated corporation a party to any arrangement (including share option scheme) to enable the Directors, Supervisors and chief executives of the Company or any of their spouses or children under eighteen years of age to hold any interests or short position in the shares or underlying shares in or debentures of the Company or its specific undertaking or other associated corporation.

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS

So far as known to the Directors, as at 31 December 2019, the followings, not being a Director, Supervisor or chief executive of the Company, had interests or short positions in the shares or underling shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or were substantial shareholders as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Long positions in shares:

Name of Shareholder	Capacity	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares	Number of H Shares	Approximate Percentage shareholding in the H Shares
Name of Shareholder	cupacity	Silares	(Note (e))	Ti Silares	(Note (f))
Hong Kong Xinsheng Pioneer Investment Company Limited	Beneficial owner	135,000,000	39.30%	-	-
Hong Kong Bio-chemical Advanced Technology Investment Company Limited	Beneficial owner	67,500,000	19.65%	-	-

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS (Continued)

Long positions in shares: (Continued)

Name of Shareholder	Capacity	Number of Foreign Shares	Approximate percentage shareholding in the Foreign Shares (Note (e))	Number of H Shares	Approximate Percentage shareholding in the H Shares (Note (f))
Jomo Limited	Beneficial owner	66,000,000	19.21%	-	-
Ms. Lam Mau	Interest of spouse, interest of controlled corporation and beneficial owner	66,000,000 (Note (a))	19.21%	2,620,000	1.43%
Kehai Venture Capital (Hong Kong) Limited	Beneficial owner	62,500,000	18.20%	_	-
上海科技創業投資股份有限公司 (Shanghai S&T Investment Company Limited*, formerly 上海科技投資股份有限公司)	Interest of controlled corporation	62,500,000 (Note (b))	18.20%	-	-
上海科技創業投資有限公司 (Shanghai Technology Entrepreneur Investment Company*, formerly 上海科技投資公司)	Interest of controlled corporation	62,500,000 (Note (c))	18.20%	-	-
上海科技創業投資(集團) 有限公司 (Shanghai S&T Venture Capital (Group) Co., Ltd.*)	Interest of controlled corporation	62,500,000 (Note (d))	18.20%	-	-

Notes:

- (a) Ms. Lam Mau and her spouse, Mr. Yu Xiao Ping (who is a Director) taken together are interested in the entire issued capital of Jomo Limited which is the registered holder and beneficial owner of 66,000,000 Foreign Shares. Ms. Lam Mau is also the beneficial owner of 2,620,000 H shares.
- (b) Shanghai S&T Investment Company Limited is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited, which is the registered holder and beneficial owner of 62,500,000 Foreign Shares.

PERSONS WHO HAVE AN INTEREST OR SHORT POSITION WHICH IS DISCLOSEABLE UNDER DIVISIONS 2 AND 3 OF PART XV OF THE SFO AND SUBSTANTIAL SHAREHOLDERS (Continued)

Long positions in shares: (Continued)

Notes: (Continued)

- (c) Shanghai Technology Entrepreneur Investment Company is the beneficial owner of 62.3% of the issued share capital of Shanghai S&T Investment Company Limited, which is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited. Kehai Venture Capital (Hong Kong) Limited is the registered holder and beneficial owner of 62,500,000 Foreign Shares.
- (d) Shanghai S&T Venture Capital (Group) Co., Ltd is the beneficial owner of 100% of the issued capital of Shanghai Technology Entrepreneur Investment Company. Shanghai Technology Entrepreneur Investment Company is the beneficial owner of 62.3% of the issued capital of Shanghai S&T Investment Company Limited, which is the beneficial owner of 100% of the issued share capital of Kehai Venture Capital (Hong Kong) Limited. Kehai Venture Capital (Hong Kong) Limited is the registered holder and beneficial owner of 62,500,000 Foreign Shares.
- (e) The percentage is calculated based on the 343,500,000 Foreign Shares in issue as at 31 December 2019.
- (f) The percentage is calculated based on the 183,700,000 H Shares in issue at 31 December 2019.

Save as disclosed above, as at 31 December 2019, the Directors are not aware of any person, not being a Director, Supervisor or chief executive of the Company, had interests or short positions in the shares or underling shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or were substantial shareholders as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

MANAGEMENT CONTRACTS

No contract concerning the management and administration of the whole or any substantial part of the business of the Company was entered into or existed during the year.

EMOLUMENT POLICY

Employees are remunerated in accordance with the nature of the job and also on individual merit.

The emoluments of the Directors and Supervisors are determined by the Remuneration Committee, with reference to their respective contribution of time, effort and expertise on the Company's matters.

The Company has adopted a staff incentive bonus scheme, please refer to the paragraph headed "Employees" under the section headed "Management Discussion and Analysis" for details.

MAJOR CUSTOMERS AND SUPPLIERS

The percentage of purchases and sales for the year attributable to the Group's major suppliers and customers are as follows:

Purchases

	2019	2018
the largest supplierfive largest suppliers combined	23% 50%	22% 54%
Sales		
	2019	2018
– the largest customer	6%	5%
- five largest customers combined	22%	21%

At no time during the year have the Directors, Supervisors, their associates or any shareholders of the Company (which to the knowledge of the Directors owns more than 5% of the Company's share capital) had any interest in these major customers and suppliers.

SHARE CAPITAL STRUCTURE

As at 31 December 2019, the category of the issued shares of the Company is as follows:

	No. of Shares
H Shares (Note (a))	183,700,000
Domestic Shares (Note (b))	2,500,000
Foreign Shares (Note (c))	343,500,000
	529,700,000

Notes:

- (a) Overseas listed foreign shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in a currency other than Rmb and are traded in Hong Kong dollars and listed on the Main Board.
- (b) Ordinary shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in Rmb and issued to the promoters of the Company.
- (c) Ordinary shares in the capital of the Company, with a Rmb-denominated par value of Rmb0.10 each, which were credited as fully paid up in a currency other than Rmb and issued to the promoters of the Company.

The H Shares were listed on GEM on 28 June 2002 and the listing of which was transferred from GEM to the Main Board on 28 June 2013.

Although the 到境外上市公司章程必備條款 (the Mandatory Provisions of the Articles of Association of Companies Seeking a Listing Outside the PRC) promulgated on 27 August 1994 by the Securities Commission of the State Council of the PRC and the State Commission for Restructuring the Economic System of the PRC provide for the definitions of "domestic shares", "foreign shares" and "overseas listed foreign shares" (which definitions have been adopted in the Articles of Association of the Company), the rights attached to Foreign Shares (which are subject to certain restrictions on transfer and may become H Shares upon obtaining the requisite approvals from, among other bodies, the China Securities Regulatory Commission and the Stock Exchange) have not yet been expressly dealt with under the existing PRC laws or regulations. However, the creation by the Company and the subsistence of the Foreign Shares do not contravene any PRC laws or regulations.

SHARE CAPITAL STRUCTURE (Continued)

At present, there are no applicable PRC laws and regulations governing the rights attached to the Foreign Shares. Jingtian & Gongcheng, the legal adviser to the Company as to PRC Law, have advised the Company that until new laws or regulations are introduced in this respect, holders of Foreign Shares shall have the same rights and obligations as those of the holders of Domestic Shares (in particular, in respect of the right to attend and vote in the general meetings and class meetings and to receive notice of such meetings in the same manner applicable to holders of Domestic Shares), except that holders of Foreign Shares shall enjoy the following rights:

- (a) to receive dividends declared by the Company in foreign currencies;
- (b) in the event of the winding up of the Company, to participate in the distribution of surplus assets (if any) of the Company in foreign currencies and transfer such assets out of PRC, subject however to the applicable foreign exchange control regulations;
- (c) disputes between holders of Domestic Shares and Foreign Shares may upon agreement between them may be resolved by way of arbitration and in case no such agreement is reached, any of the disputing parties could submit the dispute to the courts with competent jurisdiction for determination. These methods of dispute resolution apply equally to disputes between holders of Foreign Shares and overseas listed foreign shares; and
- (d) upon all necessary approvals from the relevant regulatory authorities in the PRC and the Stock Exchange being obtained, the Foreign Shares may be converted into overseas listed foreign shares and shall thereafter carry the same rights and obligations attaching to overseas listed foreign shares.

PUBLIC FLOAT

As at the date of this report, the Company has maintained the prescribed public float under the Listing Rules, based on the information that is publicly available to the Company and within the knowledge of the Directors.

RETIREMENT SCHEMES

Details of the retirement schemes are set out in Notes 2.22(a) and 12 to the consolidated financial statements.

BUSINESS REVIEW

(a) Business performance and future development

Discussion on the business performance and future development of the Group is set out in the session headed "Chairman's Statement" in this Annual Report.

Analysis of the key performance indicators of the Group is set out in the session headed "Management Discussion and Analysis" in this Annual Report.

These discussions form part of the "Report of the Directors".

(b) Environmental policies and performance

Discussions on the environment policies and performance of the Group are set out in the "Environmental and Social Report" in this Annual Report. These discussions form part of the "Report of the Directors".

(c) Laws and regulations that have a significant impact on the Company

The Group is mainly engaged in the production of organic acids products, which are used as food additives, pharmaceutical adjuvant and active pharmaceutical ingredient, etc. Accordingly, the Group is required to comply with relevant laws and regulations on environmental protection. It is also required to comply with the Law of Work Safety, Food Safety Law, Labour Contract Law and Company Law, etc. in the PRC. The H shares of the Company are listed on the Main Board, therefore the Company also needs to comply with the Listing Rules and the disclosure requirements the Hong Kong Companies Ordinance.

The Group did not aware of any material non-compliance with applicable laws and regulations that have a significant impact on the Group for the year ended 31 December 2019.

(d) Key relationships

Discussions on the relationships with employees, customers and suppliers of the Group are set out in the "Environmental and Social Report" in this Annual Report. These discussions form part of the "Report of the Directors".

BUSINESS REVIEW (Continued)

(e) Principal risks and uncertainties

Certain significant risks have been identified through the process of risk identification and assessment. A summary on such significant risks of the Group together with the relevant internal control measures or mitigation in place is listed below:

1. Research and development

The Group has two research centres. The Group will invest in research and development to improve existing production technologies and develop new production technologies each year. The Group's future prospects will be dependent upon the successful development and commercialisation of products currently under development. Successful development is, however, uncertain. There is also no assurance that a product can receive market acceptance and is competitive in the market. The Group will take into account the prospect of new markets, sales prices and costs of new products before making decision to invest in research and development to control the relevant risks.

2. Tax relief

The Group's net profit mainly comes from the company's production base in Changzhou. The Company, qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15%. If the Company is fail to renew such qualification, there will be a material impact on the Group's profit. The Company continues to actively co-ordinated different departments on monitoring the compliance of requirements on New and High Technology Enterprise qualification and strives to continue to enjoy the relevant tax relief.

3. Volatility of prices for raw materials

The Group's main raw material is butane, mainly purchased from Chinese suppliers. The price for butane are affected by various factors and the Group does not and will not control over those factors. Those factors include the prices of crude oil, global and regional supply and demand for butane, domestic and foreign government regulations, weather conditions and global economic conditions. Any increase in the price of butane which cannot be passed on to the Group's customers may adversely affect the Group's business and results of operations.

BUSINESS REVIEW (Continued)

- (e) Principal risks and uncertainties (Continued)
 - 4. Competition

Approximately 47% of the Group's products are exported overseas, while approximate 53% of the sales are in the domestic (including import and export companies) market for the year ended 31 December 2019. Whether in foreign or domestic market, food additives industry is intensively competitive. Any increase in the level of competition could result in price reduction and erode the Group's market share and gross profit margin. The Group continuously monitors and analyses the competitive situation and market information and makes early estimate to adverse movements and takes corresponding measures. The Group has also taken measures to strengthen the brand, to promote business growth and consolidate the brand's market position. In addition, the Group continues to make improvement on production technologies to reduce production costs and improve product quality so that its products will be more competitive.

SUBSEQUENT EVENT

Particulars of the subsequent event is set out in Note 36 to the consolidated financial statements in this annual report.

PERMITTED INDEMNITY PROVISIONS

At no time during the financial year and up to the date of this Directors' Report, there was or is, any permitted indemnity provision being in force for the benefit of any of the directors of the Company (whether made by the Company or otherwise) or an associated company (if made by the Company).

AUDITOR

The consolidated financial statements have been audited by PricewaterhouseCoopers who retire and, being eligible, offer themselves for re-appointment.

By order of the Board

Rui Xin Sheng Chairman

The PRC, 27 March 2020

REPORT OF THE SUPERVISORY COMMITTEE

To the Shareholders,

During the year ended 31 December 2019, the supervisory committee of Changmao Biochemical Engineering Company Limited (the "Supervisory Committee"), exercised conscientiously its authority, safeguarded the interests of the shareholders and the Company, followed the principle of trustworthiness, honestly carried out the duties of supervisors and worked cautiously and diligently, in accordance with the Company Law of the PRC, requirements of the relevant laws and regulations of Hong Kong and the Articles of Association of the Company for their accountability to the shareholders.

During the year, the major work performed by the Supervisory Committee included the attendance of the Board meetings; reviewing the report of the Directors and the reserve appropriation proposal prepared to be submitted by the Board for the shareholders' approval at the forthcoming annual general meeting; strictly and effectively monitored that whether the policies and decisions made by the management of the Company had conformed with the state laws and regulations of the PRC and the Articles of Association of the Company or safeguarded the interest of the shareholders. The Supervisory Committee has also reviewed the performance of the Directors, general manager and senior management in the daily operation by various means; seriously examined the Company's financial affairs and its connected transactions.

After the examination, the Supervisory Committee concluded that:

- 1. the report of the Directors and the reserve appropriation proposal prepared to be submitted by the Board for the shareholders' approval at the forthcoming annual general meeting are in accordance with the relevant laws and regulations and the Articles of Association of the Company;
- 2. the Directors, general manager and other senior management of the Company have strictly followed the principles of trustworthiness, worked diligently and responsibly, and discharged their duties for the best interest of the Company. The Supervisory Committee has not discovered that any Directors, general manager and other senior management of the Company have abused their powers, damaged the interest of the Company or the benefits of the shareholders and employees nor contravened any laws and regulations or the Articles of Association of the Company;

REPORT OF THE SUPERVISORY COMMITTEE

3. the consolidated financial statements of the Group for the year ended 31 December 2019, which have been audited by PricewaterhouseCoopers, reflected truly and fairly the operating results and financial position of the Company and its subsidiaries. The connected transactions were in compliance with the Listing Rules and were fair and reasonable and had not infringed upon the interest of the Company and the shareholders.

The Supervisory Committee takes this opportunity to thank the shareholders, Directors and all the employees of the Company for their supports in the past year!

By order of the Supervisory Committee

Zhou Rui Juan

Chairman of the Supervisory Committee

The PRC, 27 March 2020



羅兵咸永道

To the Shareholders of Changmao Biochemical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

OPINION

What we have audited

The consolidated financial statements of Changmao Biochemical Engineering Company Limited (the "Company") and its subsidiaries (the "Group") set out on pages 65 to 133, which comprise:

- the consolidated balance sheet as at 31 December 2019;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of changes in equity for the year then ended;
- the consolidated cash flow statement for the year then ended; and
- the notes to the consolidated financial statements, which include a summary of significant accounting policies.

Our opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2019, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters identified in our audit are summarised as follows:

- Impairment of non-financial assets of production plants in Lianyungang
- Net realisable value of inventories

Key Audit Matter

How our audit addressed the Key Audit Matter

Impairment of non-financial assets of production plants in Lianyungang

Refer to Notes 4(a), 15, 16 and 17 to the consolidated financial statements

As at 31 December 2019, the Group has certain non-financial assets, including property, plant and equipment, land use rights and construction in progress related to the production plants in Lianyungang ("Lianyungang Changmao") amounting to approximately Rmb148.1 million. The production plants in Lianyungang commenced operations since early 2016 and have been operating at loss since its commencement of operations while planned production level is still yet to be attained. The plant is also temporarily suspended as detailed in Note 4(a).

Management considered the operating losses and temporary suspension of the production of Lianyungang Changmao as impairment indicators on the non-financial assets of these plants and has performed an impairment assessment on these assets as at 31 December 2019. Based on the results of the assessment, it is concluded that no provision for impairment of the above non-financial assets of Lianyungang Changmao is required.

Our audit procedures in relation to management's assessment on impairment of non-financial assets of Lianyungang Changmao included:

- Obtained, understood and evaluated management's impairment assessment process;
- Tested the mathematical accuracy of the value-in-use calculation of the cash flow forecast and assessed the appropriateness of the methodology used. We independently evaluated the appropriateness of the key assumptions, including revenue growth rate and gross profit margin, based on other available market data in the food additives industry in the People's Republic of China taking into account the historical performance of the Group. We obtained, understood and evaluated the timing of Lianyungang Changmao's restoration of production estimated by management based on Lianyungang Changmao's correspondence with the relevant authority, including its detailed compliance assessments, and publicly available information, and did not identify any matter that is contradictory to the assumptions. We also evaluated appropriateness of the discount rate used by considering Lianyungang Changmao's weighted average cost of capital and comparable companies; and

Key Audit Matter

We focused on this area because the carrying amounts of the above non-financial assets of Lianyungang Changmao are significant to the consolidated financial statements, the existence of impairment indicators and the determination of recoverable amount of these assets, using value-in-use calculations, require significant judgements and estimates by the management about the future results of the related business and the discount rate applied to the cash flow forecast.

How our audit addressed the Key Audit Matter

Assessed the appropriateness of management's sensitivity analysis over the timing of restoration of production and the above key assumptions of the cash flow forecast in order to assess the potential impact of a range of possible outcomes and evaluated the likelihood of such a movement based on the historical experience of the Group and market trend in the industry.

Based on the procedures described above, we found the methodology used, and key assumptions and estimates applied by management in the impairment assessment of non-financial assets of Lianyungang Changmao are supportable by available evidence.

Net realisable value of inventories

Refer to Notes 4(b) and 20 to the consolidated financial statements

As at 31 December 2019, the Group held inventories of approximately Rmb106 million, net of impairment provision of approximately Rmb2 million. Inventories are carried at the lower of cost and net realisable value. Management determines the net realisable value of inventories by considering the ageing profile, estimated selling price and physical condition of the inventory on a product-by-product basis.

Management performed periodic inventory counts to identify defective or obsolete inventories.

Our audit procedures in relation to management's assessment on the net realisable value of inventories included:

- Tested key inventory controls across the Group;
- Observed inventory counts to identify defective or obsolete inventories;
- Tested, on a sample basis, the accuracy of the ageing profile of individual inventory items by checking to the underlying procurement correspondence and purchase invoices;

Key Audit Matter

How our audit addressed the Key Audit Matter

Management determined the provision for slow-moving inventories based on inventory ageing and applied judgement to make specific provision for long aged inventories.

Management also applied judgement in determining the estimated selling price less cost to sell based on historical experience of selling products of similar nature and expectation of future sales based on current market conditions and available information.

We focused on the net realisable value of inventories due to the size of the inventories balance and the judgment involved by management in determining the net realisable value of the inventories.

- Tested, on a sample basis, the estimated selling price of significant inventory items to the actual selling price subsequent to the year end or latest sales data and compared the estimated selling price of selected inventory items against its costs. We discussed with management as to its assessment on the net realisable value of the inventory items with no subsequent sales after the year end, corroborating explanations with sales orders, current market price of similar products, historical margins and marketability of relevant inventories, as appropriate; and
- Tested, on a sample basis, the subsequent utilisation of raw materials, and subsequent sales by products to identify slow moving inventories. We discussed with management to understand its provision assessment for those raw materials or products with no subsequent utilisation or sales by corroborating explanations with the inventory ageing, sales orders and marketability of the relevant inventories, as appropriate.

Based on the procedures described above, we found the assumptions made by management in relation to the assessment on net realisable value of inventories are supportable by available evidence.

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises all of the information included in the annual report other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND THE AUDIT COMMITTEE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The Audit Committee is responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Ho Chiu Yin, Ivan.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, 27 March 2020

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 December 2019

	Note	2019 Rmb′000	2018 Rmb′000
Revenue	5	494,580	639,120
Cost of sales	7	(359,425)	(509,394)
Gross profit Other income	6	135,155 3,402	129,726 4,018
Other (losses)/gains, net	6	(1,066)	1,737
Selling expenses	7	(14,064)	(15,169)
Administrative expenses	7	(60,961)	(63,554)
Reversal of loss allowance/(loss allowance)			
on financial assets	7	344	(1,304)
Operating profit		62,810	55,454
Finance income		264	296
Finance costs		(521)	(1,149)
Finance costs, net	8	(257)	(853)
Profit before income tax		62,553	54,601
Income tax expense	9	(4,626)	(4,692)
meome tax expense		(1,020)	(1,032)
Profit for the year		57,927	49,909
Other comprehensive income		51,7521	10,000
Item that may be reclassified to profit or loss			
 currency translation difference 		5	1
Total comprehensive income for the year		57,932	49,910
Profit for the year attributable to:		F0 200	50 525
Equity holders of the Company Non-controlling interests		58,299 (372)	50,525 (616)
Tyon-controlling interests		(372)	(010)
		57,927	49,909
Total comprehensive income for the year attributable to:			
Equity holders of the Company		58,304	50,526
Non-controlling interests		(372)	(616)
		57,932	49,910
			-
Earnings per share for profit attributable to			
equity holders of the Company	4.0	B 10.440	D 10005
– basic and diluted	10	Rmb0.110	Rmb0.095

CONSOLIDATED BALANCE SHEET

AS AT 31 December 2019

		2019	2018
	Note	Rmb′000	Rmb′000
ASSETS			
Non-current assets			
Patents	14	575	660
Property, plant and equipment	15	270,297	292,537
Land use rights	16	_	25,943
Right-of-use assets	15	26,174	_
Construction in progress	17	109,232	87,531
Deferred income tax assets	30	20,261	13,949
Prepayments	22	493	_
		427,032	420,620
Current assets			
Inventories	20	106,183	108,024
Trade and bills receivables	21	64,131	98,672
Other receivables, deposits and prepayments	22	16,300	16,830
Income tax recoverable		2,246	-
Derivative financial instruments	23	43	_
Pledged bank balances	24	1,588	2,774
Cash and bank balances	24	120,216	85,098
		310,707	311,398
Total assets		737,739	732,018
EQUITY			
Capital and reserves attributable to the Company's equity holders			
Share capital	25	52,970	52,970
Reserves	26	608,722	576,903
		661,692	629,873
Non-controlling interests		622	994
Total equity		662,314	630,867

CONSOLIDATED BALANCE SHEET (Continued)

AS AT 31 December 2019

		2019	2018
	Note	Rmb′000	Rmb′000
LIABILITIES			
Non-current liabilities			
Deferred income	28	1,452	1,945
Lease liabilities	15	309	_
Deferred income tax liabilities	30	571	494
		2,332	2,439
Current liabilities			
Trade and bills payables	27	20,139	19,781
Contract liabilities, other payables and accruals	28	31,799	37,055
Income tax payable		15	2,565
Lease liabilities	15	640	_
Bank borrowings	29	20,500	39,311
		73,093	98,712
Total liabilities		75,425	101,151
Total equity and liabilities		737,739	732,018

The financial statements on pages 65 to 133 were approved by the Board of Directors on 27 March 2020 and were signed on its behalf.

Rui Xin Sheng
Director

Pan Chun
Director

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 December 2019

Attributable to equity holders of the Company

	Note	Share capital Rmb'000	Other reserves	Retained earnings Rmb′000	Sub-total Rmb'000	Non- controlling interests Rmb′000	Total Rmb′000
Balance at 1 January 2018		52,970	182,981	343,396	579,347	1,610	580,957
Transfer to statutory reserve	26	_	7,272	(7,272)	_	_	_
Profit for the year		_	_	50,525	50,525	(616)	49,909
Other comprehensive income – currency translation							
difference – Group		_	1	-	1	-	1
Balance at 31 December 2018		52,970	190,254	386,649	629,873	994	630,867
Balance at 1 January 2019		52,970	190,254	386,649	629,873	994	630,867
Profit for the year		_	_	58,299	58,299	(372)	57,927
Other comprehensive income – currency translation							
difference – Group		_	5	-	5	-	5
Final dividend for the year							
ended 31 December 2018	11	_	_	(26,485)	(26,485)	_	(26,485)
Balance at 31 December 2019		52,970	190,259	418,463	661,692	622	662,314

CONSOLIDATED CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 December 2019

		2019	2018
	Note	Rmb′000	Rmb′000
Cash flows from operating activities			
Cash generated from operations	31(a)	134,576	51,819
Interest paid	<i>3</i> . (a)	(592)	(1,278)
Income tax paid		(15,657)	(6,063)
Not each generated from enerating activities		110 227	44 479
Net cash generated from operating activities		118,327	44,478
Cash flows from investing activities			
Prepayments for property, plant and equipment		(493)	_
Purchase of property, plant and equipment		(968)	(8)
Proceeds from disposal of property, plant and equipment		86	276
Additions of construction in progress		(39,805)	(32,894)
Government grants received		_	1,088
Decrease in pledged bank balances		1,186	12,897
Decrease in long-term and short-term bank deposits with			
maturities of over 3 months		2,800	1,850
Interest received		264	296
Investment income received		1,144	
Net cash used in investing activities		(35,786)	(16,495)
Cash flows from financing activities			
Principal elements of lease payments	31(b)	(299)	_
Proceeds from new bank borrowings	31(b)	20,500	73,004
Repayment of bank borrowings	31(b)	(38,873)	(88,342)
Dividends paid	31(b)	(26,485)	
Net cash used in financing activities		(45,157)	(15,338)
Net increase in cash and cash equivalents		37,384	12,645
Effect of foreign exchange rate changes		534	1
Cash and cash equivalents at 1 January		81,398	68,752
Cash and cash equivalents at 31 December	24	119,316	81,398

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1 GENERAL INFORMATION

Changmao Biochemical Engineering Company Limited (the "Company") is a joint stock limited company incorporated in the People's Republic of China (the "PRC"). The Company formerly listed its H shares on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited ("SEHK") on 28 June 2002 which was then transferred to the Main Board of the SEHK on 28 June 2013. The principal activities of the Company and its subsidiaries (together, the "Group") are the production and sales of organic acids products.

The address of the Company's registered office is No.1228 Chang Jiang Bei Road, New North Zone, Changzhou City, Jiangsu Province, 213034, the PRC.

These consolidated financial statements are presented in Renminbi, unless otherwise stated. These consolidated financial statements have been approved for issue by the Board of Directors on 27 March 2020.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated. The consolidated financial statements are for the group consisting of Changmao Biochemical Engineering Company Limited and its subsidiaries.

2.1 Basis of preparation

The consolidated financial statements of Changmao Biochemical Engineering Company Limited have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRS") and disclosure requirements of the Hong Kong Companies Ordinance Cap. 622. The financial statements have been prepared on a historical cost basis, except for derivative financial instruments which are carried at fair value.

The preparation of the consolidated financial statements in conformity with HKFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements is disclosed in Note 4.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(a) New and amended standards, improvements and interpretation adopted by the Group

The Group has applied the following new and amended standards, improvements and interpretation for the first time for their annual reporting period commencing 1 January 2019:

- HKFRS 16 "Leases"
- Amendments to HKFRS 9 "Prepayment Features with Negative Compensation"
- Amendments to HKAS 28 "Long-term Interests in Associates and Joint Ventures"
- Annual Improvements Projects "Annual Improvements 2015-2017 Cycle"
- Amendments to HKAS 19 "Plan Amendment, Curtailment or Settlement"
- Interpretation 23 "Uncertainty over Income Tax Treatments"

The Group had to change its accounting policies as a result of adopting HKFRS 16. In accordance with the transition provisions of HKFRS 16, the Group has adopted the modified retrospective application for existing leases at 1 January 2019 with certain transition reliefs and under which comparative figures are not restated. For leases previously classified as operating leases, the Group has elected to measure the right-of-use assets at the amounts equal to the lease liabilities adjusted by any prepaid or accrued lease payments. Accordingly, no adjustments were recognised to the opening balance of retained earnings at the date of initial application. This is disclosed in Note 2.1(c).

Saved as above, the adoption of these new and amended standards, improvements and interpretation did not have any impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

Effective for accounting periods

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(b) New and amended standards and revised framework not yet adopted
A number of new and amended standards and revised framework have been published that are not mandatory for the year ended 31 December 2019 and have not been early adopted by the Group.

		beginning on or after
Amendments to HKFRS 3	Definition of a Business	1 January 2020
Amendments to HKAS 1 and HKAS 8	Definition of Material	1 January 2020
Conceptual Framework for Financial Reporting 2018	Revised Conceptual Framework for Financial Reporting	1 January 2020
Amendments to HKAS 39, HKFRS 7 and HKFRS 9	Hedge Accounting	1 January 2020
HKFRS 17	Insurance Contracts	1 January 2021
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

These new and amended standards and revised framework are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1 Basis of preparation (Continued)

(c) Changes in accounting policies

This note explains the impact of the adoption of HKFRS 16 Leases on the Group's consolidated financial statements.

As indicated in Note 2.1(a) above, the Group has adopted HKFRS 16 retrospectively from 1 January 2019, but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognised in the opening consolidated balance sheet on 1 January 2019. The new accounting policies are disclosed in Note 2.27.

On adoption of HKFRS 16, the Group has a non-cancellable operating lease in respect of rental of office only. Given the remaining terms of the operating lease was less than 12 months, the Group has accounted for this lease as short-term lease under the practical expedients permitted by the standard. As such, except for the adjustment recognised in the consolidated balance sheet, there was no material impact on the Group's consolidated financial position as at 1 January 2019.

Adjustments recognised in the consolidated balance sheet on 1 January 2019
The change in accounting policy affected the following items in the consolidated balance sheet on 1 January 2019:

- Land use rights decrease by Rmb25,943,000
- Right-of-use assets increase by Rmb25,943,000

There was no impact on retained earnings at 1 January 2019

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.2 Subsidiaries

(a) Consolidation

The consolidated financial statements include the financial statements of the Company and all of its subsidiaries made up to 31 December 2019.

A subsidiary is an entity (including a structured entity) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The Group applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date.

The Group recognises any non-controlling interest in the acquiree on an acquisition-by-acquisition basis. Non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation are measured at either fair value or the present ownership interest's proportionate share in the recognised amounts of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at their acquisition date fair value, unless another measurement basis is required by HKFRS.

Acquisition-related costs are expensed as incurred.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognised in profit or loss.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.2 Subsidiaries (Continued)

(a) Consolidation (Continued)

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognised in profit or loss.

The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired is recorded as goodwill. If the total of consideration transferred, non-controlling interest recognised and previously held interest measured is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in profit or loss.

Intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

Transactions with non-controlling interests that do not result in loss of control are accounted for as equity transactions – that is, as transactions with the owners of the subsidiary in their capacity as owners. The difference between fair value of any consideration paid and the relevant share acquired of the carrying amount of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

When the Group ceases to have control, any retained interest in the entity is re-measured to its fair value at the date when control is lost, with the change in carrying amount recognised in profit or loss. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.2 Subsidiaries (Continued)

(b) Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Costs include direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

Impairment testing of investments in subsidiaries is required upon receiving dividends from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2.3 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the executive directors that makes strategic decisions.

2.4 Foreign currency translation

(a) Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in Renminbi ("Rmb"), which is the Company's functional and the Group's presentation currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss, except when deferred in other comprehensive income as qualifying cash flow hedges or qualifying net investment hedges.

All other foreign exchange gains and losses are presented in the consolidated statement of comprehensive income within "other (losses)/gains, net".

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.4 Foreign currency translation (Continued)

(c) Group companies

The results and financial position of all the Group entities (none of which has the currency of a hyper-inflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (i) assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
- (ii) income and expenses for each income statement are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions); and
- (iii) all resulting currency translation differences are recognised in other comprehensive income.

Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. Currency translation differences arising are recognised in other comprehensive income.

(d) Disposal of foreign operation and partial disposal

On the disposal of a foreign operation (that is, a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation, or a disposal involving loss of joint control over a joint venture that includes a foreign operation, or a disposal involving loss of significant influence over an associate that includes a foreign operation), all of the currency translation differences accumulated in equity in respect of that operation attributable to the equity holders of the Company are reclassified to profit or loss.

In the case of a partial disposal that does not result in the Group losing control over a subsidiary that includes a foreign operation, the proportionate share of accumulated currency translation differences are re-attributed to non-controlling interests and are not recognised in profit or loss. For all other partial disposals (that is, reductions in the Group's ownership interest in associates or joint ventures that do not result in the Group losing significant influence or joint control) the proportionate share of the accumulated exchange difference is reclassified to profit or loss.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.5 Patents

Patents are stated at cost less accumulated amortisation and accumulated impairment losses, if any. Patents are amortised using the straight-line method over their estimated useful lives as follows:

Acid patent 15 years Nutraceutical patent 19 years

Where an indication of impairment exists, the carrying amounts of the patents are assessed and written down immediately to their recoverable amounts.

2.6 Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to the profit or loss during the financial period in which they are incurred.

Depreciation on property, plant and equipment is calculated using the straight-line method to allocate their costs less accumulated impairment losses to their estimated residual values over their estimated useful lives, as follows:

Buildings 20-50 years
Plant and machinery 10 years
Equipment and motor vehicles 5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains or losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised within "other (losses)/gains, net" in the consolidated statement of comprehensive income.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.7 Land use rights

Land use rights are stated at cost less accumulated amortisation and accumulated impairment losses, if any. Land use rights are amortised using the straight-line method over their estimated useful lives of 50 years.

Where an indication of impairment exists, the carrying amounts of the land use rights are assessed and written down immediately to their recoverable amounts.

2.8 Construction in progress

Construction in progress is stated at cost, which comprises construction costs, purchase costs, interest and other direct costs incurred in connection with the construction of buildings, plant and machinery for own use, less accumulated impairment losses, if any.

No depreciation is provided for in respect of construction in progress until the construction and installation is completed and ready for their intended use, upon which they will be transferred to appropriate categories of property, plant and equipment.

2.9 Impairment of non-financial assets

Assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation/depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at each reporting date.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.10 Financial assets

(a) Classification

The Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income ("OCI") or through profit or loss), and
- those to be measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For financial assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). The Group reclassifies debt investments when and only when its business model for managing those assets changes.

(b) Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

(c) Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset.

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in "other (losses)/gains".

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.10 Financial assets (Continued)

(c) Measurement (Continued)

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Assets that do not meet the criteria for amortised cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognised in the statement of profit or loss in which it arises.

Losses allowance of financial assets are presented as separate line item in the consolidated statement of comprehensive income.

(d) Impairment

The Group assesses on a forward looking basis the expected credit losses associated with its financial assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Group applies the simplified approach permitted by HKFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 3.1(b) for further details.

2.11 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet where the Group currently has a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.12 Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

Government grants relating to costs are deferred and recognised in profit or loss over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to property, plant and equipment are included in liabilities as deferred government grants and are credited to profit or loss on a straight-line basis over the expected lives of the related assets.

2.13 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average basis. The cost of finished goods and work in progress comprises materials, direct labour and an appropriate proportion of all production overhead expenditures. It excludes borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

2.14 Trade and other receivables

Trade and other receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. If collection of trade and other receivables is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. They are generally due for settlement within 30-120 days and therefore are all classified as current.

Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The Group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. See Note 21 for further information about the Group's accounting for trade receivables and Note 3.1 for a description of the Group's impairment policies.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.15 Cash and cash equivalents

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Bank deposits with original maturities of more than three months are excluded from cash and cash equivalents.

2.16 Derivative financial instruments

Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair values at the end of each reporting period. The method of recognising the resulting gain or loss depends on whether the derivative is designed as a hedging instrument, and if so, the nature of the item being hedged.

The Group's forward foreign exchange contracts is recognised as derivatives financial instruments that do not qualify for hedge accounting, and changes in the fair value of these derivative instruments are recognised immediately in the consolidated statement of comprehensive income within "other (losses)/gains, net".

2.17 Share capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

2.18 Trade and other payables

Trade payables are obligations to pay for goods and services provided to the Group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within the normal operating cycle of the business. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.19 Borrowings

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the income statement over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting period.

2.20 Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Other borrowing costs are expensed in the period in which they are incurred.

2.21 Current and deferred income tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

(a) Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Group operates and generates taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.21 Current and deferred income tax (Continued)

(b) Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations where the company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2 **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

2.22 Employees benefits

(a) Pension obligations

The Group contributes to various employee retirement benefit plans organised by municipal and provincial governments in Mainland China for its PRC based employees. Under these plans, the municipal and provincial governments undertake to assume the retirement benefit obligations of all existing and future retired PRC based employees of the Group. Contributions to these plans are expensed as incurred. The Group has no further payment obligations once the contributions have been paid.

The Group's contributions to the Mandatory Provident Fund Scheme established under the Hong Kong Mandatory Provident Fund Schemes Ordinance are expensed as incurred. Both the Group and its employees in Hong Kong are required to contribute 5% of each individual's relevant income with a maximum amount of HK\$1,500 per month as a mandatory contribution. Employees may also elect to contribute more than the minimum as a voluntary contribution. The assets of the scheme are held separately from those of the Group and managed by independent professional fund managers. The Group has no further payment obligations once the contributions have been paid.

(b) Profit-sharing and bonus plans

The Group recognises a liability and an expense for bonuses and profit-sharing, based on a formula that takes into consideration the profit attributable to the Company's shareholders after certain adjustments. The Group recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.23 Provisions

Provisions for environmental restoration, restructuring costs and legal claims are recognised when: the Group has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Restructuring provisions comprise lease termination penalties and employee termination payments. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

2.24 Revenue recognition

The Group manufactures and sells a range of organic acids products. Sales are recognised when control of the products has transferred, being when the products are delivered to the customers, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specified location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the group has objective evidence that all criteria for acceptance have been satisfied.

Revenue from the sale of goods is based on the price specified in the sales contracts. No element of financing is deemed present as the sales are made within the credit terms, which is consistent with market practice.

Receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

Deposit collected from the customers before product delivery is recognised as contract liabilities.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.25 Interest income

Interest income is recognised on a time-proportion basis using the effective interest method.

2.26 Research and development costs

Research costs are expensed as incurred. Costs incurred on development projects relating to the design and testing of new or improved products are recognised as an intangible asset when the technical feasibility and intention of completing the product under development has been demonstrated and the resources are available to do so, costs are identifiable and there is an ability to sell or use the asset that will generate probable future economic benefits. Such development costs are recognised as an asset and amortised on the straight-line basis to reflect the pattern in which the related economic benefits are recognised. Development costs that do not meet the above criteria are expensed as incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

2.27 Leases

As explained in Note 2.1(c) above, the Group has changed its accounting policy for leases where the Group is the lessee. The new policy is described below and the impact of the change in Note 2.1(c).

Until 31 December 2018, leases in which a significant portion of the risks and rewards of ownership were not transferred to the Group as lessee were classified as operating leases (Note 32). Payments made under operating leases (net of any incentives received from the lessor) were charged to profit or loss on a straight-line basis over the period of the lease.

From 1 January 2019, leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the fixed payments (including in-substance fixed payments).

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.27 Leases (Continued)

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the group, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Right-of-use assets are measured at cost comprising the amount of the initial measurement of lease liability and any lease payments made at or before the commencement date.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.

Payments associated with short-term leases are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less.

2.28 Dividend distribution

Dividend distribution to the Company's shareholders is recognised as a liability in the Group's and the Company's financial statements in the period in which the dividends are approved by the Company's shareholders or directors, where appropriate.

3 FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks, including foreign exchange risk, credit risk, liquidity risk and cash flow and fair value interest rate risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effect on the Group's financial performance.

(a) Foreign exchange risk

The Group mainly operates in the PRC. Substantially all of its assets, liabilities and capital expenditure were located or incurred in Mainland China. Sales are made to customers in the PRC as well as overseas customers while purchases are mainly from suppliers in the PRC. The Group is therefore exposed to foreign exchange risk arising from currency exposures, primarily with respect to United States Dollars ("USD").

Management periodically monitors foreign currency exposures and considers hedging significant foreign currency exposures should the need arises. During the year, the Group used forward contracts to hedge, but do not qualify for hedge accounting, its foreign currency exposure in USD.

At 31 December 2019, if Rmb had weakened/strengthened by 5% against USD with all other variables held constant, post-tax profit for the year would have been approximately Rmb3,207,000 (2018: Rmb2,169,000) higher/lower, mainly as a result of foreign exchange gains/losses on translation of USD-denominated trade receivables, other payables, bank deposits and bank borrowings.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(b) Credit risk

(i) Risk Management

The Group's credit risk arises from cash at banks and trade and bills receivables, derivative financial instruments, other receivables and deposits. Management has a credit policy in place and the exposures to these credit risks are monitored on an ongoing basis. The carrying amounts of these balances represent the Group's maximum exposure to credit risk in relation to financial assets which are stated as follows:

	2019	2018
	Rmb′000	Rmb′000
Trade, bills and other receivables and		
deposits excluding prepayments and		
valued added tax recoverable (Note 19)	68,594	103,520
Derivative financial instruments (Note 19)	43	_
Cash at banks (Note 24)	121,804	87,872
Maximum exposure to credit risk	190,441	191,392

The credit period of the majority of the Group's trade receivables is due within 30 to 120 days and largely comprises amounts receivable from corporate customers.

In respect of trade receivables, the Group has policies in place to ensure that sales of products are made to customers with an appropriate credit history and the Group performs periodic credit evaluation of its customers, taking into account its financial position, past experience and other factors. The Directors consider the Group does not have a significant concentration of credit risk.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

- (b) Credit risk (Continued)
 - (ii) Impairment of financial assets

The Group has two types of financial assets that are subject to HKFRS 9's expected credit loss model:

- trade and bills receivables:
- other receivables and deposits, excluding prepayments and other tax receivables;
- derivative financial instruments;
- pledged bank balances and cash at bank.

Trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

To measure the expected credit losses, trade receivables have been grouped with similar risk characteristics and collectively or individually assessing them for likelihood of recovery.

The Group categorises its trade receivables, except those individually assessed, based on geographical location and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 36 months and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.

Given the track record of regular repayment of trade receivables under the collective assessment, the directors are of the opinion that the risk of default by these customers is not significant, taking into account forwardlooking information on macroeconomic factors. Therefore, expected credit loss rate of these trade receivables is assessed to be insignificant.

For trade receivables relating to accounts which are long overdue with known insolvencies or non-response to collection activities, they are assessed individually for loss allowance. Accordingly, a specific loss allowance of Rmb890,000 (2018: Rmb1,359,000) were made as at 31 December 2019.

Impairment of financial assets (Continued)

3 FINANCIAL RISK MANAGEMENT (Continued)

Financial risk factors (Continued)

- (b) Credit risk (Continued)
 - Bills receivables, derivative financial instrument and cash at bank As at 31 December 2019, substantially all of the Group's bills receivables,

bank balances and derivative financial instruments are deposited in major financial institutions located in the PRC. Management does not expect any losses from non-performance by these banks. The credit quality of cash and cash equivalents has been assessed by reference to external credit ratings or to historical information about the counterparty default rates. The existing counterparties do not have defaults in the past, therefore, the identified credit loss allowance was also immaterial (2018: same).

Other receivables and deposits

Loss allowance on other receivables and deposits from third parties are measured as either 12-months expected credit losses or lifetime expected credit losses, depending on whether there has been a significant increase in credit risk since initial recognition.

If a significant increase in credit risk of a receivable has occurred since initial recognition, then loss allowance is measured as lifetime expected credit losses. The loss allowance for other receivables and deposits have increased by Rmb25,000 (2018: increased by Rmb244,000) during the year ended 31 December 2019.

(c) Liquidity risk

The Group's primary cash requirements have been for construction of and upgrades on property, plant and equipment, repayment on related borrowings and payment for research and development expenses. The Group finances its working capital requirements through funds generated from operations and short-term bank borrowings.

Due to the dynamic nature of the underlying businesses, the Group's policy is to regularly monitor current and expected liquidity requirements, to ensure that it maintains sufficient reserves of cash and adequate lines of funding to meet its liquidity requirements in the short and long term.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(c) Liquidity risk (Continued)

The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows (including interests payments computed using contractual rates, or if floating, based on the current rates at the year end date):

	Within	Between	
	1 year	1 and 2 years	Total
	Rmb′000	Rmb′000	Rmb′000
At 31 December 2019			
Trade and bills payables	20,139	_	20,139
Other payables	22,374	_	22,374
Lease liabilities	658	329	987
Bank borrowings	20,511	_	20,511
Total	63,682	329	64,011
At 31 December 2018			
Trade and bills payables	19,781	_	19,781
Other payables	28,568	_	28,568
Bank borrowings	39,784	_	39,784
Total	88,133	_	88,133

(d) Cash flow and fair value interest rate risk

The Group's income and operating cash flows are substantially independent of changes in market interest rates and the Group has no significant interest-bearing assets except for cash and bank balances, details of which are disclosed in Note 24. The Group's exposure to changes in interest rates is mainly attributable to its short-term bank borrowings. Management intends to draw short-term bank loans so as to increase flexibility in financing.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.1 Financial risk factors (Continued)

(d) Cash flow and fair value interest rate risk (Continued)

Borrowings issued at fixed rates expose the Group to fair value interest rate risk. Borrowings issued at variable rates expose the Group to cash flow interest-rate risk. The Group will review whether bank loans bearing fixed or floating rates should be drawn from time to time with reference to the trend of changes in interest rates. The Group has not used any interest rate swaps to hedge its exposure to interest-rate risk.

At 31 December 2019, if the interest rates on borrowings had been 10 basis points higher/lower with all other variables held constant, post-tax profit for the year would have been approximately Rmb17,000 (2018: Rmb33,000) lower/higher, mainly as a result of higher/lower interest expense on bank borrowings.

3.2 Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, repurchase shares from shareholders or sell assets to reduce debt.

The Group monitors capital on the basis of the liabilities-to-assets ratio. This ratio is calculated as total liabilities divided by total assets. The Group aims to maintain the ratio at a reasonable level.

The liabilities-to-assets ratio at 31 December 2019 and 2018 was as follows:

	2019	2018
Total liabilities (Rmb'000)	75,425	101,151
Total assets (Rmb'000)	737,739	732,018
Liabilities-to-assets ratio	10.2%	13.8%

The decrease in liabilities-to-assets ratio is mainly due to the decrease in short-term bank borrowings in financing the Group's operations.

3 FINANCIAL RISK MANAGEMENT (Continued)

3.3 Fair value estimation

Financial instruments carried at fair value are analysed by valuation method below. Different levels have been defined as follows:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
- Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
- Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

At 31 December 2019, the Group had several foreign exchange forward contracts assets of carrying amounts of Rmb43,000 (2018: Nil), which were measured by level 2 of the fair value measurement hierarchy.

Majority of the carrying amount of the Group's financial assets, including cash and bank balances, pledged bank balances, trade and bills receivables, other receivables and deposits, and financial liabilities, including trade and bills payables, contract liabilities, other payables, lease liabilities and short-term bank borrowings, approximate their fair values due to their short maturities.

3.4 Offsetting financial assets and financial liabilities

No financial assets and financial liabilities were subject to offsetting, enforceable master netting arrangements and similar agreements as at 31 December 2019 and 2018.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Group's accounting policies.

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

(a) Impairment of property, plant and equipment and intangible assets

Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The recoverable amounts have been determined based on higher of fair value less cost of disposal or value-in-use calculations. These calculations require the use of judgements and estimates.

Management judgement is required in the area of asset impairment particularly in assessing: (i) whether an event has occurred that may indicate that the related asset values may not be recoverable; (ii) whether the carrying value of an asset can be supported by the recoverable amount, being the higher of fair value less costs of disposal and value-in-use which is the net present value of future cash flows which are estimated based upon the continued use of the asset in the business; and (iii) the appropriate key assumptions to be applied in preparing cash flow forecast including whether these cash flow forecast is discounted using an appropriate rate. Changing the assumptions selected by management in assessing impairment, including the discount rates, the gross profit margin or the revenue growth rate assumptions in the cash flow forecast, could affect the net present value used in the impairment test and as a result affect the Group's financial position and results of operations.

As at 31 December 2019, the Group has certain non-financial assets, including property, plant and equipment, land use rights and construction in progress related to the production plants in Lianyungang Changmao amounting to approximately Rmb148.1 million. The production plants in Lianyungang commenced operations since early 2016 and have been operating at loss since its commencement of operations while planned production level is still yet to be attained.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(a) Impairment of property, plant and equipment and intangible assets (Continued)

In early 2018, Jiangsu Provincial authority has requested all the enterprises in Lianyungang Industrial Park ("Industrial Park") to suspend production due to certain enterprises in the Industrial Park continued to experience safety and environmental accidents. The production of Lianyungang Changmao was then suspended, as Lianyungang Changmao is located in Industrial Park. However, Lianyungang Changmao has strictly complied with various laws and regulations and carried out plant construction and project approval work in accordance with national regulations since its incorporation. The Group has already registered with the relevant authority for restoration of production, which is pending for approval up to the date of this report. Management considered that the suspension shall be temporary.

As a result of the operating losses and temporary suspension of the production of Lianyungang Changmao, management has performed an impairment assessment on the non-financial assets of the plants as at 31 December 2019. Management has also performed sensitivity analysis over the key assumptions of the cash flow forecast, including future gross profit margin, revenue growth rate, discount rate and a further delay for restoration of production by 12 months, in order to assess the potential impact of a range of possible outcomes. Based on the results of the assessment, it is concluded that no provision for impairment of the above non-financial assets of Lianyungang Changmao is required.

(b) Net realisable value of inventories

The Group writes down inventories to net realisable value based on an assessment of the realisability of inventories. Provisions are made for inventories where events or changes in circumstances indicate that the balances may not be realised. The identification of obsolescence requires the use of judgement and estimates. Where the estimate is different from the original amount, such difference will impact the carrying value of inventories and net realisable value for the periods in which such estimate is changed. In addition, management has assessed the realisability of the inventories and considers that the provision for inventories impairment is adequate and reasonable in the current year.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(c) Useful lives of property, plant and equipment

The Group's management determines the estimated useful lives, residual values and related depreciation charges for the Group's property, plant and equipment, with reference to the estimated periods that the Group intends to derive future economic benefits from use of these assets. This estimate is based on the historical experience of the actual useful lives of property, plant and equipment of similar nature and functions. Management will revise the depreciation charges where useful lives or residual values are different from previously estimated, or it will write-off or write-down technically obsolete or non-strategic assets that have been abandoned or sold.

(d) Trade and other receivables

The loss allowances for trade and other receivables are based on assumptions about risk of default and expected loss rates. The group uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the group's past history, existing market conditions as well as forward looking estimates at the end of each reporting period. Details of the key assumptions and inputs used are disclosed in Note 3.1(b).

(e) Income taxes and deferred tax

The Group is subject to income taxes in Mainland China. Judgement is required in determining the provision for income taxes. There are transactions and calculations during the ordinary course of business for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Deferred income tax assets relating to certain temporary differences and tax losses are recognised when management considers it is likely that future taxable profits will be available against which the temporary differences or tax losses can be utilised. When the expectations are different from the original estimates, such differences will impact the recognition of deferred income tax assets and income tax charges in the period in which such estimates have been changed.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Continued)

(f) Research and development costs

Research costs are expensed as incurred. Costs incurred on development projects relating to the design and testing of new or improved products are recognised as an intangible asset when the technical feasibility and intention of completing the product under development has been demonstrated and the resources are available to do so, costs are identifiable and there is an ability to sell or use the asset that will generate probable future economic benefits. Significant judgement is required in determining the capitalisation of development costs. Development costs that are recognised as assets are amortised on the straight-line basis to reflect the pattern in which the related economic benefits are recognised. Development costs that do not meet the above criteria are expensed as incurred.

(g) Derecognition of financial assets and liabilities

Bills receivables are derecognised when the rights to receive cash flows from such bills receivables have matured or have been transferred and the Group has transferred substantially all the risks and rewards of ownership. If a transfer does not result in derecognition because the Group has retained substantially all the risks and rewards of ownership of the transferred bills receivables, the Group shall continue to recognise the transferred bills receivables in its entirety and shall continue to recognise the corresponding financial liability to be settled until the transferred bills receivables matured. Significant judgement is required in determining whether the bills receivables will be honoured by the financial institution upon its maturity.

During the year, the Group has reassessed the criteria for the derecognition of transferred bills receivables. Such change in accounting estimate has been applied prospectively from 1 January 2019 onwards. As a result, both bills receivables and financial liabilities as at 31 December 2019 has been increased by approximately Rmb15,497,000 respectively.

5 REVENUE AND SEGMENT INFORMATION

Executive directors are identified as the chief operating decision maker. Management has determined the operating segments based on the information reported to the executive directors for the purposes of allocating resources and assessing performance.

The Group is engaged in the production and sales of organic acids products. Resources of the Group are allocated based on what is beneficial to the Group in enhancing the value as a whole rather than any specific unit, and the executive directors consider the performance assessment of the Group should be based on the results of the Group as a whole. Therefore, management considers there to be only one operating segment under the requirement of HKFRS 8.

	2019	2018
	Rmb′000	Rmb′000
Revenue from sales of goods, recognised at a point in time	494,580	639,120
An analysis of the Group's revenue by geographic location is as	follows:	
	2019	2018
	Rmb′000	Rmb′000
Mainland China	263,554	324,745
Europe	101,066	112,698
Asia Pacific	81,087	142,815
America	36,748	43,887
Others	12,125	14,975
	494,580	639,120

5 REVENUE AND SEGMENT INFORMATION (Continued)

Europe region mainly includes the Great British, Germany, Turkey, Spain and Italy whereas Asia Pacific region mainly includes Hong Kong, Indonesia, Australia, India, Thailand and Japan.

The analysis of revenue by geographic location is based on the country area in which the customer is located. No analysis of contribution by geographic location has been presented as the ratio of profit to revenue achieved for individual geographic location is not substantially out of line with the Group's overall ratio of profit to revenue.

As at 31 December 2019, all the Group's non-current assets (other than the deferred income tax assets) amounted to Rmb406,771,000 (2018: Rmb406,671,000) are located in Mainland China.

Included in the revenue from sales of goods, approximately Rmb29,933,000 (2018: Rmb33,580,000) was contributed by the Group's largest customer and the aggregate revenue from this customer represented approximately 6% (2018: 5%) of the total revenue of the Group. There are no single customers contributing over 10% of the Group's total revenue.

Assets and liabilities related to contract with customers

The Group has not recognised any contract assets related to contract with customers as at 31 December 2019.

- (i) Significant changes in contract liabilities

 Contract liabilities have been decreased by Rmb1,000,000 due to a decrease in overall contract activities.
- (ii) Revenue recognised in relation to contract liabilities

 Revenue of Rmb2,935,000 is recognised in relation to contract liabilities in the year ended 31 December 2019 related to carried forward contract liabilities as at 1 January 2019. There is no revenue recognised in relation to contract liabilities satisfied on or before 1 January 2019.
- (iii) All contracts are for the periods of one year or less or are billed based on time incurred. As permitted under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

OTHER INCOME AND OTHER (LOSSES)/GA	•	0.04.0
	2019 Rmb′000	2018 Rmb′000
	KIIID 000	KIIID OOK
Other income		
Sales of scrap materials	30	43
Government grants	1,632	1,61
Others	1,740	2,35
	3,402	4,018
	2019	2018
	Rmb′000	Rmb′000
Other (losses)/gains, net		
Fair value gains on derivative financial instruments	43	
Loss on disposal of property, plant and equipment	(2,144)	(79
Net exchange gains	1,035	1,81
	(1,066)	1,73
EXPENSES BY NATURE		
LAILINGES DI NATORE	2019	2018
	Rmb′000	Rmb′000
Cost of inventories sold	191,650	310,764
Amortisation of patents (Note 14)	85	84
Amortisation of land use rights (Note 16)		699
Auditors' remuneration – audit services	1,321	1,367
Depreciation of property, plant and equipment (Note 15	5) 34,279	33,587
Depreciation of right-of-use assets (Note 15)	995	-
Research and development costs	10,302	8,67
(Reversal of loss allowance)/loss allowance on		
financial assets	(344)	1,304
Provision for inventories to net realisable value	698	
Staff costs (including emoluments of Directors		
and Supervisors) (Note 12)	65,477	69,859
	43,502	58,922
Utilities		104 150
Other expenses	86,141	104,158

7 **EXPENSES BY NATURE** (Continued)

Included in research and development costs are mainly expenditures incurred for the formulation, design, evaluation and application of various forms of organic acids products for commercial use. Management assessed that those internal projects are in the research and initial development stage, and did not recognise any of those expenditure as an asset.

8 FINANCE COSTS, NET

	2019	2018
	Rmb′000	Rmb′000
Interest for lease liabilities	(30)	_
Interest on bank borrowings	(491)	(1,149)
	(521)	(1,149)
Interest income on bank deposits	264	296
Finance costs, net	(257)	(853)

9 INCOME TAX EXPENSE

PRC Corporate Income Tax ("CIT") is provided for on the basis of the profit for statutory financial reporting purposes, adjusted for income and expense items which are not assessable or deductible for income tax purposes. The Company, being qualified as a New and High Technology Enterprise, is entitled to a preferential CIT rate of 15%. Other subsidiaries of the Group in Mainland China are subject to a standard tax rate of 25%.

The amount of income tax charged to consolidated statement of comprehensive income represents:

	2019	2018
	Rmb′000	Rmb′000
Current income tax		
Provision for CIT	11,387	9,852
- Over-provision in prior year	(526)	(9)
Deferred income tax (Note 30)	(6,235)	(5,151)
	4,626	4,692

9 **INCOME TAX EXPENSE** (Continued)

The tax on the Group's profit before income tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to the results of the consolidated entities as follows:

	2019	2018
	Rmb′000	Rmb′000
Profit before income tax	62,553	54,601
Calculated at the tax rates applicable to results of	6.005	- 0
the respective consolidated entities	6,285	5,257
Expenses not deductible for tax purposes	533	1,162
Tax losses for which no deferred income		
tax asset was recognised	683	533
Timing differences for which no deferred income		
tax asset was recognised	(120)	_
Reversal of previously recognised tax losses	320	_
Tax incentives for research and development expenses*	(2,373)	(2,198)
Over-provision in prior year	(526)	(9)
Others	(176)	(53)
Income tax expense	4,626	4,692

^{*} According to relevant laws and regulations promulgated by the State Administration of Tax of the PRC effective from 2008 onwards, enterprises engaging in research and development activities are entitled to claim 175% (2018: 175%) of their qualified research and development expenses so incurred as tax deductible expenses when determining their assessable profits for the year ("Super Deduction"). The Group has made its best estimate for the Super Deduction to be claimed in ascertaining the assessable profits for the years ended 31 December 2019 and 2018.

10 EARNINGS PER SHARE

The calculation of basic earnings per share for the year ended 31 December 2019 is based on the profit attributable to the equity holders of the Company of Rmb58,299,000 (2018: Rmb50,525,000) and 529,700,000 (2018: 529,700,000) weighted average number of shares in issue during the year.

The Company had no dilutive potential shares in issue during the year (2018: Nil).

11 DIVIDENDS

No interim dividend was declared during the year (2018: Nil). The dividend paid in 2019 was 26,485,000 (Rmb0.05 per share) (2018: Nil). A final dividend in respect of the year ended 31 December 2019 of Rmb0.055 per share, totalling Rmb29,134,000 is to be proposed at the Annual General Meeting on 25 May 2020. These financial statements do not reflect this dividend payable.

12 STAFF COSTS

Staff costs including Directors' and Supervisors' remuneration are as follows:

	2019	2018
	Rmb′000	Rmb′000
Salaries, wages and related welfare	48,650	56,302
	,	,
Social security costs	10,820	6,713
Contribution to defined contribution retirement schemes (Note)	6,007	6,844
	65,477	69,859

Note: The Group is required to participate in defined contribution retirement schemes organised by the relevant local government authorities for its PRC based employees. Contributions to the retirement schemes are payable at a rate of 16% (2018: 19%) of the total salaries and allowances of the PRC based employees, subject to a ceiling, and the Group has no further retirement benefit obligations to all its existing and future retired PRC based employees.

13 EMOLUMENTS OF SUPERVISORS AND SENIOR MANAGEMENT

(a) The remuneration of each of the Supervisors of the Company for the year ended 31 December 2019 is set out as follows:

	Fees Rmb'000	Salaries Rmb'000	Discretionary Bonus Rmb'000	Housing Allowance Rmb'000	money value of other benefit Rmb′000	Retirement benefits contributions Rmb′000	Total Rmb'000
Ms. Zhou Rui Juan	15	24	-	_	-	-	39
Mr. Lu A Xing	6	391	-	-	-	38	435
Mr. Zhang Jun Peng	6	229	-	-	-	20	255
Prof. Jiang Yao Zhong	15	-	-	-	-	-	15
Mr. Geng Gang	15	-	-	-	-	-	15

The remuneration of each of the Supervisors of the Company for the year ended 31 December 2018 is set out as follows:

					Estimated		
					money value	Retirement	
			Discretionary	Housing	of other	benefits	
	Fees	Salaries	Bonus	Allowance	benefit	contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Ms. Zhou Rui Juan	15	48	_	-	-	_	63
Mr. Lu A Xing	6	180	-	-	-	19	205
Mr. Zhang Jun Peng	6	194	-	-	-	22	222
Prof. Jiang Yao Zhong	15	-	-	-	-	-	15
Mr. Geng Gang	15	-	-	-	-	-	15

None of the supervisors received or will receive any retirement benefits or termination benefits during the financial year (2018: Nil).

13 EMOLUMENTS OF SUPERVISORS AND SENIOR MANAGEMENT (Continued)

(b) Five highest paid individuals

Among the five highest paid individuals, two (2018: two) of them are Directors of the Company and the details of their remuneration are disclosed in Note 35(a). The emoluments of the remaining three highest paid individual are as follows:

	2019 Rmb′000	2018 Rmb′000
Basic salaries, allowances and benefits in kind	1,610	1,456
Discretionary bonus	262	251
Retirement benefit contributions	72	102
	1,944	1,809

The emoluments fell within the following bands:

	Number of individuals	
	2019	2018
Emolument bands (in Hong Kong dollars)		
Nil to HK\$1,000,000	2	3
HK\$1,000,001 to HK\$1,500,000	1	-

(c) Senior management remuneration by band Save as disclosed in Note 13(b) above, all senior management's (who are not Directors nor Supervisors) emolument fall within the band of HK\$0 – HK\$1,000,000 (2018: same).

14 PATENTS

TATENTS		
	2019	2018
	Rmb′000	Rmb′000
Net book amount, at 1 January	660	744
Amortisation charge (Note 7)	(85)	(84)
Net book amount, at 31 December	575	660
	2019	2018
	Rmb′000	Rmb′000
At cost	11,600	11,600
Accumulated amortisation	(11,025)	(10,940)
Net book amount, at 31 December	575	660

15 PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS

TROTERTI, TEART AND E	Equipment				
	Buildings Rmb′000	Plant and machinery Rmb'000	and motor vehicles Rmb′000	Total Rmb′000	
At 1 January 2018					
Cost	177,993	413,399	41,610	633,002	
Accumulated depreciation	(65,812)	(236,461)	(31,492)	(333,765)	
Net book amount	112,181	176,938	10,118	299,237	
Year ended 31 December 2018					
Opening net book amount	112,181	176,938	10,118	299,237	
Additions	_	_	8	8	
Transfer from construction in		26.024	2.45	27.224	
progress (Note 17) Disposals	55 (12)	26,934 (245)	245 (98)	27,234 (355)	
Depreciation (Note 7)	(8,260)	(23,369)	(1,958)	(33,587)	
Closing net book amount	103,964	180,258	8,315	292,537	
	,				
At 31 December 2018	170.022	420 112	40.240	(57.202	
Cost Accumulated depreciation	178,032 (74,068)	439,112 (258,854)	40,248 (31,933)	657,392 (364,855)	
- Teedinatated depreciation	(7 1,000)	(230,031)	(31,733)	(301,033)	
Net book amount	103,964	180,258	8,315	292,537	
Year ended 31 December 2019					
Opening net book amount	103,964	180,258	8,315	292,537	
Additions	_	121	847	968	
Transfer from construction in	210	12.001		12 201	
progress (Note 17) Disposals	210 (602)	13,091 (1,553)	- (75)	13,301 (2,230)	
Depreciation (Note 7)	(8,253)	(24,131)	(1,895)	(34,279)	
Closing net book amount	95,319	167,786	7,192	270,297	
At 31 December 2019					
Cost	176,977	446,749	40,028	663,754	
Accumulated depreciation	(81,658)	(278,963)	(32,836)	(393,457)	
Net book amount	95,319	167,786	7,192	270,297	
	/	,	. , =		

Depreciation expense of Rmb28,486,000 (2018: Rmb27,750,000) and Rmb5,793,000 (2018: Rmb5,837,000) were charged in "cost of sales" and "administrative expenses" respectively for the year ended 31 December 2019.

15 PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS (Continued)

This note provides information for leases where the Group is a lessee.

The Group's right-of-use assets and lease liabilities mainly arise from lease of four land use rights located in Mainland China with typically lease terms of 50 years and an office premises. The lease agreements do not impose any covenants, but leased assets were not used as security for borrowing purposes.

(i) Amounts recognised in the consolidated balance sheet

The consolidated balance sheet shows the following amounts relating to leases:

	31 December 2019 Rmb'000	1 January 2019 Rmb′000
Right-of-use assets		
Land use rights	25,255	25,943
Office premises	919	_
	26,174	25,943
Lease liabilities		
Current	640	_
Non-current	309	
	949	_

Additions to the right-of-use assets during the 2019 financial year were Rmb1,226,000.

(ii) Amounts recognised in the statement of profit or loss

The statement of profit or loss shows the following amounts relating to leases:

	Note	2019 Rmb′000	2018 Rmb′000
Depreciation charge of right-of-use assets	7	995	_
Interest expense (included in finance cost)	8	30	_
Expense relating to leases of low-value assets			
that are not shown above as short-term			
leases (included in administrative expenses)		257	_

The total cash outflow for leases in 2019 was Rmb586,000.

16 LAND USE RIGHTS

The Group's interests in land use rights represent prepaid operating lease payments for land use rights on four pieces of land located in Mainland China and their net book value are analysed as follows:

	2018
	Rmb′000
Net book amount, at 1 January	26,642
Amortisation charge	(699)
Net book amount, at 31 December	25,943
	2018
	Rmb′000
At cost	34,259
Accumulated amortisation	(8,316)
Net book amount, at 31 December	25,943

From 1 January 2019, land use rights are included in right-of-use asset (Note 15). Please refer to Note 2.1(c) for details about changes in accounting policy.

17 CONSTRUCTION IN PROGRESS

	2019	2018
	Rmb′000	Rmb′000
A. 4.1	07.534	70.006
At 1 January	87,531	79,826
Additions	35,002	34,939
Transfer to property, plant and equipment (Note 15)	(13,301)	(27,234)
At 31 December	109,232	87,531

During the year ended 31 December 2019, no borrowing costs were capitalised.

18 SUBSIDIARIES

Details of the principal subsidiaries at 31 December 2019 are as follows:

Name	Place of establishment, operations and kind of legal entity	Particulars of registered and paid up capital	Interest directly held	Interest indirectly held	Principal activities
上海常茂生物化學工程 有限公司 (Shanghai Changmao Biochemical Engineering Company Limited)	PRC, limited liability company	Rmb20,000,000	100%	-	Trading of organic acids products and property holding
上海醫學生命科學研究中心 有限公司 (Shanghai Medica Life Science Research Centre Limited) (Note a)	PRC, limited I liability company	Rmb15,384,600	57.44%	-	Research and development of medicine and nutraceutical products
常茂生物連雲港有限公司 (Changmao Biochemical Lianyungang Company Limited)	PRC, limited liability company	Rmb50,000,000	100%	-	Sales and production of food additives
Changmao (Hong Kong) Company Limited	Hong Kong, limited company	HKD1	100%	-	Trading of organic acids products
維萌(上海)商貿有限公司 (Shanghai Vitalements Trading Co., Ltd.)	PRC, limited liability company	Registered capital: Rmb1,000,000	-	100%	General trading
		Paid up capital: Rmb2,000			

Note a: No summarised financial information of Shanghai Medical Life Science Research Centre Limited is presented as the non-controlling interest is not material to the Group.

19 FINANCIAL INSTRUMENTS BY CATEGORY

FINANCIAL INSTRUMENTS BY CATEGOR	Y	
	2019	2018
	Rmb′000	Rmb′000
Financial assets		
Financial assets at amortised cost		
Trade and bills receivables	64,131	98,672
Other receivables and deposits excluding	04,131	90,072
prepayments and value-added tax receivables	4,463	4,848
Pledged bank balances	1,588	2,774
Cash and bank balances	120,216	85,098
Cash and Dank Dalances	120,216	65,096
Financial assets at fair value through profit or loss		
Derivative financial instruments	43	_
Total	190,441	191,392
	2019	2018
	Rmb′000	Rmb′000
Financial liabilities		
Financial liabilities at amortised cost		
Bank borrowings	20,500	39,311
Trade and bills payables	20,139	19,781
Other payables excluding accruals and contract lial		28,568
Financial liabilities at fair value through profit or loss		
Lease liabilities	949	_
Lease Habilities		
Total	63,962	87,660
10(4)	03,302	07,000

20 INVENTORIES

	2019 Rmb′000	2018 Rmb′000
Raw materials	40,141	43,192
Work-in-progress	7,675	6,642
Finished goods – at cost	58,367	58,190
	106,183	108,024

As at 31 December 2019, provision for impairment of inventories amounting to Rmb2,019,000 (2018: Rmb1,321,000).

The cost of inventories recognised as expense and include in "cost of sales" amounted to 191,650,000 (2018: 310,764,000) which included provision for inventories to net realisable value of Rmb 698,000 (2018: Nil).

21 TRADE AND BILLS RECEIVABLES

	2019	2018
	Rmb′000	Rmb′000
Trade receivables	48,584	98,672
Bills receivables	15,547	
	64,131	98,672

21 TRADE AND BILLS RECEIVABLES (Continued)

(a) The credit terms of trade receivables range from 30 to 120 days and the ageing analysis which is based on the invoice date of trade receivables is as follows:

	2019	2018
	Rmb′000	Rmb′000
0 to 3 months	44,217	94,340
4 to 6 months	5,074	4,972
Over 6 months	183	719
	49,474	100,031
Less: Loss allowance (Note 3.1)	(890)	(1,359)
	48,584	98,672

- (b) The maturity dates of bills receivables are normally within 6 months.
- (c) Loss allowance of trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Note 3.1(b) provides for details about the allowance.

Information about the impairment of trade receivables and the Group's exposure to foreign exchange risk and credit risk can be found in Note 3.1.

21 TRADE AND BILLS RECEIVABLES (Continued)

(c) Loss allowance of trade receivables (Continued)

The closing loss allowances for all trade receivables reconcile to the opening loss allowances are as follows:

	Rmb′000
Loss allowance as at 1 January 2018	1,985
Trade receivables written off during the year as uncollectible	(1,686)
Loss allowance for trade receivables	1,060
Loss allowance as at 31 December 2018	1,359
Trade receivables written off during the year as uncollectible	(100)
Reversal of loss allowance for trade receivables	(369)
Loss allowance as at 31 December 2019	890

Any loss allowance of trade receivables is separately presented in the consolidated statement of comprehensive income. The amounts charged to the allowance account are generally written off, when there is no expectation of recovering additional cash.

(d) The carrying amounts of trade and bills receivables approximate their fair values and are denominated in the following currencies:

	2019	2018
	Rmb′000	Rmb′000
Rmb	32,661	25,536
USD	31,470	73,136
	64,131	98,672

(e) The maximum exposure to credit risk at the reporting date is the fair value of each class of receivables mentioned above. The Group does not hold any collateral as security.

22 OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS

,	2019 Rmb′000	2018 Rmb′000
Prepayments and deposits	6,155	8,307
Value-added tax receivables	8,234	7,595
Other receivables	2,404	928
	16.703	16.020
	16,793	16,830
Less: Non-current portion		
Prepayments for property, plants and equipment	(493)	_
Current portion	16,300	16,830

23 DERIVATIVE FINANCIAL INSTRUMENTS

As at 31 December 2019, derivative financial instruments represented foreign exchange forward contracts that were not qualified for hedge accounting under the requirement of HKAS 39. These contracts were used to sell USD for Rmb.

The notional principal amounts of the outstanding forward foreign exchange contracts at 31 December 2019 were approximately Rmb17,343,000 (2018: Nil). These foreign exchange forward contracts held for trading were expected to be settled within 12 months.

24 PLEDGED BANK BALANCES AND CASH AND BANK BALANCES

	2019	2018
	Rmb′000	Rmb′000
Short-term bank deposits with original		
maturities of over 3 months	900	3,700
Cash and cash equivalents	119,316	81,398
Cash and bank balances	120,216	85,098
Pledged bank balances	1,588	2,774
Total	121,804	87,872

24 PLEDGED BANK BALANCES AND CASH AND BANK BALANCES (Continued)

(Communication)	2019 Rmb′000	2018 Rmb′000
Denominated in:		
– Rmb	77,056	70,089
– USD	44,537	17,381
– HKD	211	402
	121,804	87,872

The effective interest rate on long-term bank deposits and short-term bank deposits with original maturities of over 3 months are ranged from 1.35% to 1.75% (2018: 1.35% to 2.25%) per annum. These deposits have remaining maturities ranged from 1 months to 8 months (2018: 3 months to 5 months) as at 31 December 2019.

Cash at banks earn interest at floating rates based on daily bank deposit rates.

The conversion of Renminbi denominated balances into foreign currencies and the remittance of these funds out of the Mainland China is subject to relevant rules and regulations of foreign exchange control promulgated by the PRC government.

Bank balances of Rmb1,588,000 (2018: Rmb2,774,000) have been pledged to a bank to secure the Group's bills financing facilities as at 31 December 2019.

25 SHARE CAPITAL

Registered, issued and fully paid:

	Share capital	
	Number of	
	shares at	Nominal
	Rmb0.10	Value
	each	Rmb′000
At 31 December 2019 and 2018	529,700,000	52,970

As at 31 December 2019 and 2018, the share capital of the Company comprised 2.5 million domestic shares, 343.5 million promoter foreign shares and 183.7 million H shares. The H shares rank pari passu with the domestic shares and promoter foreign shares in all aspects and rank equally for all dividends or distributions declared, paid or made except that all dividends in respect of H shares are to be paid by the Company in Hong Kong dollars and H shares may only be subscribed by legal or natural persons of Hong Kong, Macau, Taiwan or any country other than the PRC.

26 RESERVES

		Statutory				
	Share	common	Capital	Exchange	Retained	
	Premium	reserve	reserve	reserve	earnings	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January 2018	102,559	79,961	461	_	343,396	526,377
Transfer to statutory common reserve	_	7,272	/	_	(7,272)	_
Profit for the year	_	- 7,272	_	_	50,525	50,525
Other comprehensive income – currency translation					30,323	30,323
difference – Group	_	_	_	1	_	1
At 31 December 2018	102,559	87,233	461	1	386,649	576,903
		Statutory				
	Share	common	Capital	Exchange	Retained	
	premium	reserve	reserve	reserve	earnings	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January 2019	102,559	87,233	461	1	386,649	576,903
Profit for the year	_	_	_	_	58,299	58,299
Other comprehensive income – currency translation					30,233	30,233
difference – Group	_	_	_	5	_	5
Final dividend for the year ended						
31 December 2018	_	-	_	-	(26,485)	(26,485)
At 31 December 2019	102,559	87,233	461	6	418,463	608,722

26 RESERVES (Continued)

Statutory common reserve

According to the Company's Articles of Association, the Company is required to transfer 10% of its profit after tax, as determined in accordance with the PRC accounting rules and regulations, to statutory common reserve until the reserve balance reaches 50% of the registered capital. The transfer to this reserve must be made before distribution of a dividend to shareholders.

Statutory common reserve can be used to make good previous years' losses, if any, to expand the business operations of the Company and may be converted into share capital by the issuance of new shares to shareholders in proportion to their existing shareholdings or by increasing the par value of the shares currently held by them, provided that the balance after such issue is not less than 25% of the registered capital of the Company.

27 TRADE AND BILLS PAYABLES

	2019 Rmb'000	2018 Rmb′000
Trade payables Bills payables	14,845 5,294	10,535 9,246
	20,139	19,781

(a) The ageing analysis of trade payables which is based on the invoice date of trade payables is as follows:

	2019 Rmb′000	2018 Rmb′000
0 to 6 months	13,642	10,247
7 to 12 months	822	40
Over 12 months	381	248
	14,845	10,535

- (b) The maturity dates of bills payables are normally within 3 months.
- (c) The carrying amounts of trade and bills payables approximate their fair values and are all denominated in Rmb.

28	CONTRACT	LIABILITIES.	OTHER	PAYABLES	AND ACCRUALS
----	-----------------	--------------	--------------	-----------------	--------------

2019	2018
Rmb′000	Rmb′000
0.530	7.400
,	7,492
5,963	10,767
2,398	3,398
1,984	2,655
1,944	2,435
1,919	4,234
1,625	2,070
8,879	5,949
33,251	39,000
 (1,452)	(1,945)
31,799	37,055
	Rmb'000 8,539 5,963 2,398 1,984 1,944 1,919 1,625 8,879 33,251 (1,452)

29 BANK BORROWINGS

The maturity of borrowings is as follows:

	2019 Rmb′000	2018 Rmb′000
Within 1 year	20,500	39,311
Denominated in:	20.500	1 000
– RMB – USD	20,500	1,000 38,311
	20,500	39,311

The carrying amounts of the Group's bank borrowings approximate their fair values.

As at 31 December 2019, the effective interest rate of the bank borrowings was 3.9% (2018: 3.8%).

30 DEFERRED INCOME TAX

The gross movement on the deferred income tax account is as follows:

	2019	2018
	Rmb′000	Rmb′000
At 1 January	13,455	8,304
Credited to the statement of comprehensive income (Note 9)	6,235	5,151
At 31 December	19,690	13,455

The movements in deferred income tax assets and liabilities during the year, without taking into consideration of the offsetting of balances within the same tax jurisdiction, are as follows:

Deferred income tax assets:

	Deferred			
	income	Provisions	Tax losses	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January 2018	449	1,063	7,276	8,788
(Charged)/credited to the consolidated statement of comprehensive income	(51)	(62)	5,274	5,161
At 31 December 2018	398	1,001	12,550	13,949
(Charged)/credited to the consolidated statement of comprehensive income	(90)	128	6,274	6,312
At 31 December 2019	308	1,129	18,824	20,261

30 DEFERRED INCOME TAX (Continued)

Deferred income tax liabilities:

	Deferred expense Rmb′000	Accelerated tax depreciation Rmb'000	Fair value gain on patents Rmb'000	Total Rmb′000
At 1 January 2018 (Credited)/charged to the consolidated	67	231	186	484
statement of comprehensive income	(67)	98	(21)	10
At 31 December 2018 Charged/(credited) to the consolidated	-	329	165	494
statement of comprehensive income	_	98	(21)	77
At 31 December 2019	_	427	144	571

Deferred income tax assets are recognised for tax losses carry-forwards to the extent that the realisation of the related tax benefits through the future taxable profits is probable. The Group did not recognise deferred income tax assets of approximately Rmb3,313,000 (2018: Rmb2,319,000) in respect of losses amounting to approximately Rmb13,252,000 (2018: Rmb9,277,000) that can be carried forward against future taxable income. The unrecognised tax losses will expire in the following years:

	2019 Rmb′000	2018 Rmb′000
2020	2,730	1,452
2021	1,901	1,901
2022	3,789	3,789
2023	2,101	2,135
2024	2,731	
	13,252	9,277

The Group had no unrecognised deferred income tax liabilities as at 31 December 2019 (2018: Nil).

31 NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT

(a) Reconciliation of profit before income tax to net cash generated from operations

	2019	2018
	Rmb′000	Rmb′000
Profit before income tax	62,553	54,601
Adjustments for:		
Interest income	(264)	(296)
Investment income	(1,144)	_
Interest expense	521	1,149
Unrealised exchange difference	(945)	(146)
Fair value gain on derivative financial instruments	(43)	_
Government grants	_	(1,618)
Amortisation of patents	85	84
Depreciation	35,274	33,587
Loss on disposal of property, plant and equipment	2,144	79
Amortisation of land use rights	-	699
(Reversal of loss allowance)/loss allowance on		
financial assets	(344)	1,304
Provision for inventories to net realisable value	698	
	98,535	89,443
Changes in working capital:		
Inventories	1,143	7,311
Trade and bills receivables, other receivables,		
deposits and prepayments	35,415	(5,407)
Trade and bills payables, contract liabilities,		
other payables and accruals	(26)	(39,528)
Deferred income	(491)	
Cash generated from operations	134,576	51,819
Cash generated from operations	134,370	31,013

31 NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT (Continued)

(b) Analysis of changes in financing during the year

	Lease liabilities		Bank borrowings		Dividends	s payable
	2019	2018	2019	2018	2019	2018
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
At 1 January	_	_	39,311	54,007	_	_
Additions - leases	1,226	_	_	_	_	_
New bank borrowings	_	_	20,500	73,004	_	_
Repayment of principals	(299)	_	(38,873)	(88,342)	_	_
Interest paid	(30)	_	_	_	_	_
Interest accretion	30	_	_	_	_	-
Exchange difference	22	_	(438)	642	_	_
2018 final dividend	_	_	_	_	26,485	_
Dividends paid	_	_	_		(26,485)	
At 31 December	949	-	20,500	39,311	_	_

32 COMMITMENTS

(a) Capital commitments for property, plant and equipment are as follows:

	2019	2018
	Rmb′000	Rmb′000
Contracted but not provided for	6,652	12,328

32 COMMITMENTS (Continued)

(b) Commitments under operating leases

The Group leases various offices and warehouses under non-cancellable operating leases.

From 1 January 2019, the group has recognised right-of-use assets for these leases, except for short-term and low-value leases, see Note 15 for further information.

	2019	2018
	Rmb′000	Rmb′000
Not later than one year	_	260
Later than one year and not later than five years	_	_
		260

33 RELATED PARTY TRANSACTIONS

(a) Key management compensation

	2019	2018
	Rmb′000	Rmb′000
Salaries and other short-term employee benefits	3,043	2,249
Retirement benefit contributions	38	43
	3,081	2,292

(b) Transactions with a related party

The following transactions derived from bank borrowing with a related party are interest-free and with short turnover days:

	2019	2018
	Rmb′000	Rmb′000
Received from a related party (Note)	20,500	35,648
Payment to a related party (Note)	12,000	38,000

Note: The transactions did not constitute connected transactions as defined in Chapter 14A of the Listing Rules.

34 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY BALANCE SHEET OF THE COMPANY

AS AT 31 December 2019

		2019	2018
		Rmb′000	Rmb′000
ASSETS			
Non-current assets			
Property, plant and equipment		194,615	210,604
Land use rights		194,013	7,932
Right-of-use assets		- 8,619	7,932
Construction in progress		28,548	8,059
Investments in subsidiaries		72,794	72,794
Deferred income tax assets		685	932
Prepayments		193	932
Тераушень		199	
		305,454	300,321
Current assets			
Inventories		91,211	89,593
Trade and bills receivables		64,081	98,145
Other receivables, deposits and prepayments		4,973	7,630
Amounts due from subsidiaries		11,042	10,134
Loans to a subsidiary		208,000	185,000
Income tax recoverable		2,245	_
Derivative financial instruments		43	_
Pledged bank balances		1,588	2,774
Cash and bank balances		116,485	79,103
		499,668	472,379
Total assets		805,122	772,700
EQUITY			
Capital and reserves attributable to			
the Company's equity holders			
Share capital		52,970	52,970
Reserves	Note (a)	681,019	625,167
Total equity		733,989	678,137

0040

0040

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

34 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY (Continued)

BALANCE SHEET OF THE COMPANY (Continued)

AS AT 31 December 2019

	2019	2018
	Rmb′000	Rmb′000
LIABILITIES		
Non-current liability		
Deferred income	1,452	1,945
Lease liabilities	309	
	1,761	1,945
Current liabilities		
Trade and bills payables	20,124	19,746
Contract liabilities, other payables and accruals	28,108	30,996
Income tax payable	_	2,565
Lease liabilities	640	_
Bank borrowings	20,500	39,311
	69,372	92,618
Total liabilities	71,133	94,563
Total equity and liabilities	805,122	772,700

The balance sheet of the Company was approved by the Board of Directors on 27 March 2020 and was signed on its behalf

Rui Xin Sheng
Director

Pan Chun
Director

34 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY (Continued)

Note (a) Reserve movement of the Company

	Share premium Rmb′000	common reserve Rmb′000	Retained earnings Rmb′000	Total Rmb′000
	KIIID 000	KIIID 000	KIIID 000	KIIID 000
At 1 January 2018	102,559	79,961	369,254	551,774
Transfer to statutory common				
reserve	_	7,272	(7,272)	_
Profit and total comprehensive income for the year	_	_	73,393	73,393
·				
At 31 December 2018	102,559	87,233	435,375	625,167
		Statutory		
	Share	common	Retained	
	premium	reserve	earnings	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000
				Killb 000
At 1 January 2019	102,559	87,233	435,375	625,167
At 1 January 2019 Profit and total comprehensive	102,559	87,233	435,375	
,	102,559	87,233 -	435,375 82,337	
Profit and total comprehensive income for the year Final dividend for the year	102,559	87,233 -	·	625,167
Profit and total comprehensive income for the year	102,559	87,233 - -	·	625,167

35 BENEFITS AND INTERESTS OF DIRECTORS

(a) Directors' and chief executive's emoluments

The remuneration of each of the Directors and chief executive officer's of the Company for the year ended 31 December 2019 is set out as follows:

					Estimated		
					money value	Retirement	
			Discretionary	Housing	of other	benefit	
Name of Director	Fees	Salaries	bonus	allowance	benefits	contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Executive director							
Mr. Rui Xin Sheng	320	480	1,049	-	-	-	1,849
Mr. Pan Chun (Note (i))	100	745	349	-	-	38	1,232
Non-executive director							
Mr. Zeng Xian Biao	50	-	175	-	-	-	225
Mr. Yu Xiao Ping	50	-	175	-	-	-	225
Ms. Leng Yi Xin	50	-	175	-	-	-	225
Mr. Wang Jian Ping	50	-	175	-	-	-	225
Independent non-executive director							
Prof. Ouyang Ping Kai	60	-	-	-	-	-	60
Prof. Yang Sheng Li (Note)	30	-	-	-	-	-	30
Ms. Wei Xin	60	-	-	-	-	-	60
Ms. Au Fung Lan	60	-	-	-	-	-	60

Note:

Prof. Yang Sheng Li resigned as the independent non-executive director on 17 June 2019.

35 BENEFITS AND INTERESTS OF DIRECTORS (Continued)

(a) Directors' and chief executive's emoluments (Continued)

The remuneration of each of the Directors and chief executive officer's of the Company for the year ended 31 December 2018 is set out as follows:

					Estimated		
			Discretionary	Housing	money value of other	Retirement benefit	
Name of Director	Fees Salarie	Salaries	bonus	allowance	benefits	contributions	Total
	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000	Rmb′000
Executive director							
Mr. Rui Xin Sheng	320	480	603	-	-	-	1,403
Mr. Pan Chun (Note (i))	100	545	201	-	-	43	889
Non-executive director							
Mr. Zeng Xian Biao	50	-	101	-	-	-	151
Mr. Yu Xiao Ping	50	-	101	-	-	-	151
Ms. Leng Yi Xin	50	-	101	-	-	-	151
Mr. Wang Jian Ping	50	-	101	-	-	-	151
Independent non-executive director							
Prof. Ouyang Ping Kai	60				_		60
Prof. Yang Sheng Li	60				_		60
Ms. Wei Xin	60	_	_	_	_	_	60
Ms. Au Fung Lan	60	_	_	_	_	_	60

Notes:

- (i) Mr. Pan is also the chief executive officer of the Company
- (ii) None of the Directors waived any emoluments during the years ended 31 December 2019 and 2018.
- (iii) No remuneration paid to or receivables by the Directors of the Company in respect of accepting office as director or director's other services in connection with the management of the affairs of the Company or its subsidiary undertaking.

35 BENEFITS AND INTERESTS OF DIRECTORS (Continued)

(b) Directors' retirement benefits and termination benefits

None of the directors received or will receive any retirement benefits or termination benefits during the financial year (2018: Nil).

- (c) Consideration provided to third parties for making available directors' services
 - During the financial year ended 31 December 2019, the Company did not pay consideration to any third parties for making available directors' services (2018: Nil).
- (d) Information about loans, quasi-loans and other dealings in favour of directors, controlled bodies corporate by and connected entities with such directors
 - As at 31 December 2019, there were no loans, quasi-loans and other dealing arrangements in favour of directors, controlled bodies corporate by and controlled entities with such directors (2018: Nil).
- (e) Directors' material interests in transactions, arrangements or contracts

No significant transactions, arrangements and contracts in relation to the Group's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year (2018: Nil).

36 SUBSEQUENT EVENT

Since early 2020, the epidemic of Coronavirus Disease 2019 ("the COVID-19 outbreak") has spread across China and other countries, and it has affected business and economic activities to some extent. Pending development of such subsequent non-adjusting event, the Group's financial results may be affected, the extent of which could not be estimated as at the date of this report. The Group will pay close attention to the development of the COVID-19 outbreak, perform further assessment of its impact and take relevant measures.

FIVE YEAR SUMMARY

	2015 Rmb′000	2016 Rmb′000	2017 Rmb′000	2018 Rmb′000	2019 Rmb′000
Consolidated results					
Revenue	514,779	594,402	630,841	639,120	494,580
Revenue	311,773	331,102	030,011	033,120	13 1,300
Operating profit	50,320	34,437	1,215	55,454	62,810
Finance income/(costs), net	687	364	29	(853)	(257)
Profit before income tax	51,007	34,801	1,244	54,601	62,553
Income tax (expense)/credit	(5,861)	(1,485)	1,456	(4,692)	(4,626)
Profit for the year	45,146	33,316	2,700	49,909	57,927
Profit for the year attributable to:					
Equity holders of the Company	45,274	33,172	3,382	50,525	58,299
Non-controlling interest	(128)	144	(682)	(616)	(372)
Dividends	13,772	10,594	-	26,485	29,134
Consolidated assets and liabilities					
Total non-current assets	402,748	400,861	416,937	420,620	427,032
Total current assets	327,456	275,497	315,445	311,398	310,707
Total current liabilities	(160,633)	(85,044)	(148,511)	(98,712)	(73,093)
Net current assets	166,823	190,453	166,934	212,686	237,614
Total assets less current liabilities	569,571	591,314	583,871	633,306	664,646
Total non-current liabilities	(264)	(2,461)	(2,914)	(2,439)	(2,332)
Total Holl-current Habilities	(204)	(2,401)	(2,314)	(2,433)	(2,332)
Net assets	569,307	588,853	580,95 <i>7</i>	630,867	662,314
Earnings per share	D 1	D 16	D 16	D 16	D 1
- basic and diluted	Rmb0.085	Rmb0.063	Rmb0.006	Rmb0.095	Rmb0.110

GLOSSARY

Board of Directors of the Company

CG Code Code provisions of Corporate Governance Code in

appendix 14 of the Listing Rules

Changmao or the Company Changmao Biochemical Engineering Company Limited

Changzhou Xinsheng 常州新生生化科技開發有限公司

Chirotechnology Centre The Jiangsu Biochemical Chirotechnology Research

Centre

CIT Corporate Income Tax

Concurrent Production Technology The concurrent production technology for the

production of fumaric acid and malic acid

Director(s) Director(s) of the Company

Domestic Shares Domestic shares of the Company

Foreign Shares Foreign shares of the Company

GEM Growth Enterprise Market of the Exchange

GMP Good Manufacturing Practices

Group The Company and its subsidiaries

H Shares H shares of the Company

HK Biochem Ltd Hong Kong Bio-chemical Advanced Technology

Investment Company Limited

HK Xinsheng Ltd Hong Kong Xinsheng Pioneer Investment Company

Limited

Lianyungang Changmao Changmao Biochemical Lianyungang Company

Limited, a subsidiary of the Company

Exchange

GLOSSARY

Main Board The securities market operated by the Stock Exchange

prior to the establishment of GEM (excluding the options market) which continues to be operated by the Stock Exchange in parallel with GEM, and for avoidance of doubt, it does not include GEM for the

purpose hereof

Model Code Model Code for Securities Transactions by Directors of

Listed Issuers as set out in Appendix 10 to the Listing

Rules

PQQ Pyrroloquinoline quinone

PRC The People's Republic of China

Rmb Renminbi

SFO Securities and Futures Ordinance

Shanghai Changmao Biochemical Engineering

Company Limited, a subsidiary of the Company

Shanghai Life Science Research Centre Limited

Shuguang Factory Changzhou Shuguang Factory (常州曙光化工廠)

Stock Exchange The Stock Exchange of Hong Kong Limited

Supervisor(s) Supervisor(s) of the Company

USD United States Dollars